



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07H 21/00, 19/04, C12N 9/00, C07K 14/08, C12N 15/85, 15/86, C12Q 1/70</b>		A3	(11) International Publication Number: <b>WO 98/28317</b>
			(43) International Publication Date: <b>2 July 1998 (02.07.98)</b>
(21) International Application Number: <b>PCT/US97/23936</b>		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>19 December 1997 (19.12.97)</b>		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(30) Priority Data:</b> 60/034,444 24 December 1996 (24.12.96) US 60/037,998 13 February 1997 (13.02.97) US 60/042,464 31 March 1997 (31.03.97) US		<b>(88) Date of publication of the international search report:</b> <b>3 September 1998 (03.09.98)</b>	
<b>(71) Applicant:</b> RIBOZYME PHARMACEUTICALS, INC. [US/US]; 2950 Wilderness Place, Boulder, CO 80301 (US).			
<b>(72) Inventors:</b> KARPEISKY, Alexander, 420 Vernier Avenue, Lafayette, CO 80026 (US). BEIGELMAN, Leonid; 5530 Colt Drive, Longmont, CO 80503 (US). MATEJULIC-ADAMIC, Jasenka; 760 South 42nd Street, Boulder, CO 80303 (US).			
<b>(74) Agents:</b> SILVERSTEIN, Gary, H. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).			

**(54) Title:** SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES

**(57) Abstract**

Novel nucleosides, process for chemical synthesis of nucleosides and incorporation of the nucleosides into polynucleotides are disclosed. Also described are polynucleotides, such as antisense, TFO and nucleic acid catalysts with one or more modifications, such as 2'-O-amino, L-nucleotides and the others.

**Best Available Copy**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Int'l. Appl. No  
PCT/US 97/23936

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6	C07H21/00	C07H19/04	C12N9/00	C07K14/08	C12N15/85
	C12N15/86	C12Q1/70			

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6	C07H	C12N	C07K	C12Q
-------	------	------	------	------

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 11304 A (RIBOZYME PHARM INC) 27 April 1995 see the whole document ---	1
A	WO 95 01363 A (HOECHST AKTIENGESELLSCHAFT) 12 January 1995 see abstract ---	1
A	EP 0 227 844 A (TEIJIN LIMITED) 8 July 1987 see abstract ---	1
A	WO 95 11910 A (RIBOZYME PHARM INC) 4 May 1995 see claim 1 ---	1
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 April 1998

Date of mailing of the international search report

20.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5810 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

SCOTT, J

## INTERNATIONAL SEARCH REPORT

Int'l. Appl. No
PCT/US 97/23936

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 18736 A (RIBOZYME PHARM INC) 20 June 1996 see the whole document ---	1
A	M.PERBOST ET AL.: "Synthesis of 5'-O-Amino-2'-deoxypyrimidine and Purine Nucleosides : Building-Blocks for Antisense Oligonucleotides." JOURNAL OF ORGANIC CHEMISTRY, vol. 60, no. 16, 11 August 1995, pages 5150-5156, XP002062165 cited in the application see the whole document ---	1
A	K.BURGESS ET AL.: "Synthesis of an Oxyamide Linked Nucleotide Dimer and Incorporation into Antisense Oligonucleotide Sequences." JOURNAL OF THE CHEMICAL SOCIETY CHEMICAL COMMUNICATIONS, 21 April 1994, pages 915-916, XP002062166 cited in the application see the whole document ---	1
A	WO 93 12130 A (BOEHRINGER MANNHEIM GMBH) 24 June 1993 see claims 1-14; figures 1,2 -----	1

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 97/23936

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-4, 26-29, 39-45; 5-25, 30-38 (partially)

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-4,26-29,39-45 completely : 5-25,30-38 partially

Nucleosides, nucleotides and polynucleotides with the 2'-O-N moiety; pharmaceutical compositions containing them; mammalian cells comprising them; methods of making the polynucleotides; use of the nucleosides or nucleotides as antiviral agents, and methods of preparing them.

2. Claims: 5-25,30-38 partially

Nucleosides and nucleotides of formula I, claim 5 where R1 is NOT OR3 where R3 is -NHR4; polynucleotides containing these nucleosides or nucleotides; mammalian cells comprising nucleosides and nucleotides of formula I, claim 5 where R1 is NOT OR3 where R3 is -NHR4; methods of making the polynucleotides; use of the nucleosides or nucleotides as antiviral agents.

3. Claims: 46-75

Nucleic acid catalysts comprising at least one L-nucleoside; mammalian cells comprising them; pharmaceutical compositions containing them; and their use.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/23936

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9511304 A	27-04-1995	AU	7978694 A	08-05-1995
WO 9501363 A	12-01-1995	DE	4321946 A	12-01-1995
		AU	7073594 A	24-01-1995
		CA	2165971 A	12-01-1995
		EP	0707591 A	24-04-1996
		FI	956341 A	19-02-1996
		JP	8512039 T	17-12-1996
		NO	955352 A	14-02-1996
EP 227844 A	08-07-1987	AU	593271 B	08-02-1990
		AU	6136786 A	10-02-1987
		DE	3685315 A	17-06-1992
		WO	8700435 A	29-01-1987
		US	4868162 A	19-09-1989
WO 9511910 A	04-05-1995	AU	8088694 A	22-05-1995
		CA	2174339 A	04-05-1995
		EP	0725788 A	14-08-1996
		JP	9504297 T	28-04-1997
WO 9618736 A	20-06-1996	US	5612215 A	18-03-1997
		US	5716824 A	10-02-1998
		US	5627053 A	06-05-1997
		US	5672501 A	30-09-1997
		AU	4412096 A	03-07-1996
		CA	2207593 A	20-06-1996
		EP	0799313 A	08-10-1997
		US	5731295 A	24-03-1998
		US	5767263 A	16-06-1998
		US	5672511 A	30-09-1997
WO 9312130 A	24-06-1993	DE	4140463 A	17-06-1993
		EP	0624161 A	17-11-1994
		JP	2621123 B	18-06-1997
		JP	7500610 T	19-01-1995

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C07H 19/00, 21/00		A2	(11) International Publication Number: <b>WO 98/28317</b>  (43) International Publication Date: 2 July 1998 (02.07.98)									
<p>(21) International Application Number: PCT/US97/23936</p> <p>(22) International Filing Date: 19 December 1997 (19.12.97)</p> <p>(30) Priority Data:</p> <table> <tr><td>60/034,444</td><td>24 December 1996 (24.12.96)</td><td>US</td></tr> <tr><td>60/037,998</td><td>13 February 1997 (13.02.97)</td><td>US</td></tr> <tr><td>60/042,464</td><td>31 March 1997 (31.03.97)</td><td>US</td></tr> </table> <p>(71) Applicant: RIBOZYME PHARMACEUTICALS, INC. [US/US]; 2950 Wilderness Place, Boulder, CO 80301 (US).</p> <p>(72) Inventors: KARPEISKY, Alexander; 420 Vernier Avenue, Lafayette, CO 80026 (US). BEIGELMAN, Leonid; 5530 Colt Drive, Longmont, CO 80503 (US). MATULIC-ADAMIC, Jasenka; 760 South 42nd Street, Boulder, CO 80303 (US).</p> <p>(74) Agents: SILVERSTEIN, Gary, H. et al.; Lyon &amp; Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p>		60/034,444	24 December 1996 (24.12.96)	US	60/037,998	13 February 1997 (13.02.97)	US	60/042,464	31 March 1997 (31.03.97)	US	<p>(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
60/034,444	24 December 1996 (24.12.96)	US										
60/037,998	13 February 1997 (13.02.97)	US										
60/042,464	31 March 1997 (31.03.97)	US										
<p>(54) Title: CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES</p> <p style="text-align: center;">Cleavage Site</p>												
<p>(57) Abstract</p> <p>Novel nucleosides, process for chemical synthesis of nucleosides and incorporation of the nucleosides into polynucleotides are disclosed. Also described are polynucleotides, such as antisense, TFO and nucleic acid catalysts with one or more modifications, such as 2'-O-amino, L-nucleotides and the others.</p>												

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES

### Background of the Invention

5 This invention relates to novel nucleoside analogs, chemical synthesis of these analogs, and their incorporation into polynucleotides

The following is a brief description of nucleoside and chemical modification of oligonucleotides. This summary is not meant to be complete but is provided only for understanding of the invention that follows. This summary is not an admission that all of the work described below is prior art 10 to the claimed invention.

Nucleoside modifications of bases and sugars, have been discovered in a variety of naturally occurring RNA (e.g., tRNA, mRNA, rRNA; reviewed by Hall, 1971 *The Modified Nucleosides in Nucleic Acids*, Columbia University Press, New York; Limbach *et al.*, 1994 *Nucleic Acids Res.* 22, 15 2183). In an attempt to understand the biological significance, structural and thermodynamic properties, and nuclease resistance of these nucleoside modifications in nucleic acids, several investigators have chemically synthesized nucleosides, nucleotides and phosphoramidites with various base and sugar modifications and incorporated them into oligonucleotides.

20 Uhlmann and Peyman, 1990, *Chem. Reviews* 90, 543, review the use of nucleoside modifications to stabilize antisense oligonucleotides.

Usman *et al.*, International PCT Publication Nos. WO/93/15187; and WO 95/13378; describe the use of sugar, base and backbone modifications to enhance the nuclease stability of enzymatic nucleic acid molecules.

25 Eckstein *et al.*, International PCT Publication No. WO 92/07065 describe the use of sugar, base and backbone modifications to enhance the nuclease stability of enzymatic nucleic acid molecules.

Grasby *et al.*, 1994, *Proc. Indian Acad. Sci.*, 106, 1003, review the "applications of synthetic oligoribonucleotide analogues in studies of RNA 30 structure and function".

Eaton and Pieken, 1995, *Annu. Rev. Biochem.*, 64, 837, review sugar, base and backbone modifications that enhance the nuclease stability of RNA molecules

5 Hildbrand and Leumann, 1996, *Agnew. Chem. Int. Ed. Engl.*, 35, 1968, describe a method for the synthesis of a 2-aminopyridine nucleoside derivative.

Mitsunobu, 1981, *Synthesis*, 1, 1-28, described a process for the conversion of alcohol (ROH) to aminoxy alcohol (RONH<sub>2</sub>).

10 The process described by Mitsunobu (*supra*) has been applied in the conversion of sugars and disaccharides (Grochowski *et al.*, 1976, 50, C15; *Synthesis* 1976, 682; *J. Bull. Pol. Acad. Sci. Chem. Commun.*, 1987, 35, 255; Tronchet *et al.*, 1982, *Helv. Chim. Acta.*, 65, 1404; *Carbohydr. Res.*, 1990, 204).


15 The process described by Mitsunobu (*supra*) has also been applied in the synthesis of 3'-O-NH<sub>2</sub> nucleosides and 5'-O-NH<sub>2</sub> nucleosides (Nielsen, 1995, *Annu. Rev. Biomol. Struc.*, 24, 167; Burgess *et al.*, 1994, *J. Chem. Soc. Chem. Commun.*, 915; Kondo *et al.*, 1985, *Am. Chem. Soc. Symp. Ser.*, 16, 93; Vasseur *et al.*, 1992, *J. Am. Chem. Soc.*, 114, 4006; Tronchet *et al.*, 1994, 13, 2071; Perbost *et al.*, 1995, *J. Org. Chem.*, 60, 5150).

20 The information disclosed in the references cited above are distinct from the presently claimed invention since they do not disclose and/or contemplate the processes for the synthesis of the methoxy nucleosides as claimed in the instant invention.

Summary of the Invention


This invention relates to novel nucleoside analogs having the Formula

I:



5       wherein, R1 is independently H, OH, O-R<sub>3</sub>, where R<sub>3</sub> is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, and ester; C-R<sub>3</sub>, where R<sub>3</sub> is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; 10       halo, NHR<sub>4</sub> (R<sub>4</sub>=alkyl (C1-22), acyl (C1-22), substituted or unsubstituted aryl), or OCH<sub>2</sub>SCH<sub>3</sub>(methylthiomethyl); X is independently a nucleotide base selected from a group consisting of 2-fluoropyridine-3-yl, pyridin-2-one-3-yl, pyridin-2-(4-nitrophenylethyl)-one-3-yl, 2-bromopyridine-5-yl, pyridin-2-one-5-yl, 15       2-aminopyridine-5-yl, and pyridin-2-(4-nitrophenylethyl)-one-5-yl; Y is independently a phosphorus-containing group; and R2 is independently DMT or a phosphorus-containing group.

In one preferred embodiment the invention features novel nucleoside analogs having the Formula II:



wherein, R1 is independently H, OH, O-R<sub>3</sub>, where R<sub>3</sub> is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; C-R<sub>3</sub>, where R<sub>3</sub> is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; halo, NHR<sub>4</sub> (R<sub>4</sub>=alkyl (C1-22), acyl (C1-22), substituted or unsubstituted aryl), or OCH<sub>2</sub>SCH<sub>3</sub>(methylthiomethyl); X is independently a nucleotide base selected from a group consisting of 2-fluoropyridine-3-yl, 2-bromopyridine-5-yl, pyridin-2-one-5-yl, and 2-aminopyridine-5-yl; Y is independently a phosphorus-containing group; and R2 is independently DMT or a phosphorus-containing group.


This invention further relates to a nucleoside or a nucleotide comprising a nucleic acid sugar portion, wherein the 2' position of said sugar has the formula: 2'-O-NHR1, wherein R1 is independently H, aminoacyl group, peptidyl group, biotinyl group, cholesteryl group, lipoic acid residue, retinoic acid residue, folic acid residue, ascorbic acid residue, nicotinic acid residue, 6-aminopenicillanic acid residue, 7-aminocephalosporanic acid residue, alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide or ester. The invention also relates to a nucleoside or a

nucleotide comprising a nucleic acid sugar portion, wherein the 2' position of said sugar has the formula: 2'-O-N=R3, wherein R3 is independently pyridoxal residue, pyridoxal-5-phosphate residue, 13-cis-retinal residue, 9-cis-retinal residue, alkyl, alkenyl, alkynyl, alkylaryl, carbocyclic alkylaryl, or heterocyclic alkylaryl

5


This invention relates to novel nucleoside analogs having the Formula

III:




wherein, R1 is independently H, aminoacyl group, peptidyl group, biotinyl group, cholesteryl group, lipoic acid residue, retinoic acid residue, 10 folic acid residue, ascorbic acid residue, nicotinic acid residue, 6-aminopenicillanic acid residue, 7-aminocephalosporanic acid residue, alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide or ester; X is independently a nucleotide base or its analog or hydrogen; Y is independently a phosphorus-containing group; and R2 is independently 15 blocking group or a phosphorus-containing group.

In a preferred embodiment the invention features novel nucleoside analogs having the Formula IV:



wherein, R3 is independently pyridoxal residue, pyridoxal-5-phosphate residue, 13-cis-retinal residue, 9-cis-retinal residue, alkyl, alkenyl, alkynyl, alkylaryl, carbocyclic alkylaryl, or heterocyclic alkylaryl; X is independently a nucleotide base or its analog or hydrogen; Y is independently a phosphorus-containing group; and R2 is independently blocking group or a phosphorus-containing group.

In a preferred embodiment, the invention features a nucleic acid catalyst comprising at least one L-nucleotide, wherein the L-nucleotide has the formula V:



wherein, X is a nucleic acid base, which may be modified or unmodified, or H; Y is a phosphorus-containing group; R1 is H, OH or other

2'-modifications; R2 is a blocking group or a phosphorus-containing group.

A "blocking group" is a group which is able to be removed after polynucleotide synthesis and/or which is compatible with solid phase polynucleotide synthesis.

5 A "phosphorus containing group" can include phosphorus in forms such as dithioates, phosphoramidites and/or as part of an oligonucleotide.

In a preferred embodiment, the invention features a process for synthesis of novel nucleoside analogs of formula I-V.

10 By "alkyl" group is meant a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxy, cyano, alkoxy, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH.

15 The term "alkenyl" group refers to unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or 20 unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, NO<sub>2</sub>, halogen, N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH.

25 The term "alkynyl" refers to an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino or SH.

30 An "aryl" group refers to an aromatic group which has at least one ring having a conjugated  $\pi$  electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally

substituted. The preferred substituent(s) on aryl groups are halogen, trihalomethyl, hydroxyl, SH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups.

5 An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above).

"Carbocyclic aryl" groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted.

10 "Heterocyclic aryl" groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted.

15 An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or hydrogen.

An "ester" refers to an -C(O)-OR', where R is either alkyl, aryl, alkylaryl or hydrogen.

20 In yet another preferred embodiment, the invention features the incorporation of novel nucleoside analogs of Formula I-V, 2'-O-methyl or 3'-O-methyl nucleosides or combinations thereof, into polynucleotides. These novel nucleoside analogs can be incorporated into polynucleotides enzymatically. For example by using bacteriophage T7 RNA polymerase, these novel nucleoside analogs can be incorporated into RNA at one or more positions (Milligan *et al.*, 1989, *Methods Enzymol.*, 180, 51).  
25 Alternatively, novel nucleoside analogs can be incorporated into polynucleotides using solid phase synthesis (Brown and Brown, 1991, in *Oligonucleotides and Analogues: A Practical Approach*, p. 1, ed. F. Eckstein, Oxford University Press, New York; Wincott *et al.*, 1995, *Nucleic Acids Res.*, 23, 2677; Beaucage & Caruthers, 1996, in *Bioorganic Chemistry: Nucleic Acids*, p 36, ed. S. M. Hecht, Oxford University Press, New York).

30 The novel nucleosides of formula I-V and/or 2'-O-methyl or 3'-O-

5 methyl nucleosides can be used for chemical synthesis of nucleotides, nucleotide-tri-phosphates and/or phosphoramidites as a building block for selective incorporation into oligonucleotides. These oligonucleotides can be used as an antisense molecule, 2-5A antisense chimera, triplex forming oligonucleotides (TFO) or as an enzymatic nucleic acid molecule. The oligonucleotides can also be used as probes or primers for synthesis and/or sequencing of RNA or DNA.

10 The novel nucleoside analogs of Formula I-V or combinations thereof, can also be independently or in combination used as an antiviral, anticancer or an antitumor agent. These compounds can also be independently or in combination used with other antiviral, anticancer or an antitumor agents.

15 By "antisense" it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm *et al.*, 1993 *Nature* 365, 566) interactions and alters the activity of the target RNA (for a review see Stein and Cheng, 1993 *Science* 261, 1004).

20 By "2-5A antisense chimera" it is meant, an antisense oligonucleotide containing a 5' phosphorylated 2'-5'-linked adenylate residues. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence *et al.*, 1993 *Proc. Natl. Acad. Sci. USA* 90, 1300).

25 By "triplex forming oligonucleotides (TFO)" it is meant an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval-Valentin *et al.*, 1992 *Proc. Natl. Acad. Sci. USA* 89, 504).

30 This invention relates to nucleic acid catalysts with one or more L-nucleotide-substitutions. These substitutions alone or in combination with other D- and L-chemical substitutions protect the nucleic acids from nuclease degradation without entirely inhibiting their catalytic activity. Resistance to nuclease degradation can increase the half-life of these

nucleic acids inside a cell and improve the overall effectiveness of nucleic acid catalysts. These modifications may also be used to facilitate efficient uptake of nucleic acid catalysts by cells, transport and localization of these nucleic acids within a cell, and help achieve an overall improvement in the 5 efficacy of nucleic acid catalysts *in vitro* and *in vivo*.

The term "chemical substitution" as used herein refers to any base, sugar and/or phosphate modification that will protect the nucleic acids from degradation by nucleases without inhibiting their catalytic activity entirely.

In one preferred embodiment the invention features a nucleic acid 10 catalyst made up entirely of L-nucleotides of Formula **V** and has no D-nucleotide residue (L-nucleic acid catalyst). More specifically, the L-nucleic acid catalyst is an RNA or a DNA or combinations of ribo- and deoxyribonucleotides. Alternately, or in addition, the L-nucleic acid catalyst is modified at the base, sugar, and/or phosphate backbone individually or in 15 combinations without entirely inhibiting the catalytic activity.

In another preferred embodiment the invention features a nucleic acid catalyst comprising at least two L-nucleotide substitutions of formula **V**, wherein said substitution is same or different.

In yet another preferred embodiment, the invention features a nucleic 20 acid catalyst with L-nucleotide substitution of Formula **V**, wherein said nucleic acid can cleave a separate nucleic acid molecule, preferably a single-stranded nucleic acid, more specifically RNA.

In a preferred embodiment the invention features a nucleic acid catalyst with L-nucleotide substitution of Formula **V**, wherein the catalyst is 25 in a hammerhead or a hairpin ribozyme motif.

In another aspect, the invention features a nucleic acid catalyst with L-nucleotide substitution of Formula **V**, wherein said nucleic acid ligates separate nucleic acid molecules.

The invention also features a nucleic acid molecule catalyst with L- 30 nucleotide substitution of Formula **V**, wherein said nucleic acid molecule

cleaves or forms amide or peptide linkages.

The term "nucleotide" is used as recognized in the art to include natural bases, and modified bases well known in the art. Such bases are generally located at the 1' position of a sugar moiety. Nucleotide generally 5 comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (see for example, Usman and McSwiggen, *supra*; Eckstein *et al.*, International PCT Publication No. WO 92/07065; Usman *et al.*, International PCT Publication No. WO 93/15187; all hereby incorporated by reference herein). There are 10 several examples of modified nucleic acid bases known in the art and has recently been summarized by Limbach *et al.*, 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-limiting examples of base modifications that can be introduced into enzymatic nucleic acids without significantly effecting their catalytic activity include, inosine, purine, pyridin-4-one, pyridin-2-one, 15 phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyluracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine) and others (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). By 20 "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases may be used within the catalytic core of the enzyme and/or in the substrate-binding regions.

There are several examples in the art describing sugar modifications 25 that can be introduced into enzymatic nucleic acid molecules without significantly effecting catalysis and significantly enhancing their nuclease stability and efficacy. Sugar modification of enzymatic nucleic acid molecules have been extensively described in the art (see Eckstein *et al.*, *International Publication* PCT No. WO 92/07065; Perrault *et al.* *Nature* 30 1990, 344, 565-568; Pieken *et al.* *Science* 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.* 1992, 17, 334-339; Usman *et al.*

5 *International Publication* PCT No. WO 93/15187; Sproat, *US Patent* No. 5,334,711 and Beigelman *et al.*, 1995 *J. Biol. Chem.* 270, 25702). Such publications describe the location of incorporation of modifications and the like, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein.

In a preferred embodiment the invention features a nucleic acid catalyst with non-nucleotide substitution. The non-nucleotide substitution are in addition to the L-nucleotide substitution and/or the non-nucleotide substitution for example in Formula V, is in the opposite enantiomeric form 10 as the standard non-nucleotide residue. The term "non-nucleotide" as used herein include either abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid or polyhydrocarbon compounds. Specific examples include those described by Seela and Kaiser, *Nucleic Acids Res.* 1990, 18:6353 and *Nucleic Acids Res.* 1987, 15:3113; Cload and Schepartz, 15 *J. Am. Chem. Soc.* 1991, 113:6324; Richardson and Schepartz, *J. Am. Chem. Soc.* 1991, 113:5109; Ma *et al.*, *Nucleic Acids Res.* 1993, 21:2585 and *Biochemistry* 1993, 32:1751; Durand *et al.*, *Nucleic Acids Res.* 1990, 18:6353; McCurdy *et al.*, *Nucleosides & Nucleotides* 1991, 10:287; Jschke 20 *et al.*, *Tetrahedron Lett.* 1993, 34:301; Ono *et al.*, *Biochemistry* 1991, 30:9914; Arnold *et al.*, International Publication No. WO 89/02439; Usman *et al.*, International Publication No. WO 95/06731; Dudycz *et al.*, International Publication No. WO 95/11910 and Ferentz and Verdine, *J. Am. Chem. Soc.* 1991, 113:4000, all hereby incorporated by reference herein. Thus, in a preferred embodiment, the invention features an enzymatic 25 nucleic acid molecule having one or more non-nucleotide moieties, and having enzymatic activity to cleave an RNA or DNA molecule. By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound 30 is abasic in that it does not contain a commonly recognized nucleotide base,

such as adenine, guanine, cytosine, uracil or thymine. The term "abasic" or "abasic nucleotide" as used herein encompasses sugar moieties lacking a base or having other chemical groups in place of base at the 1' position.

5 In preferred embodiments, the enzymatic nucleic acid includes one or more stretches of RNA, which provide the enzymatic activity of the molecule, linked to the non-nucleotide moiety. The necessary RNA components are known in the art, see, e.g., Usman, *supra*. By RNA is meant a molecule comprising at least one ribonucleotide residue:

10 As the term is used in this application, non-nucleotide-containing enzymatic nucleic acid means a nucleic acid molecule that contains at least one non-nucleotide component which replaces a portion of a ribozyme, e.g., but not limited to, a double-stranded stem, a single-stranded "catalytic core" sequence, a single-stranded loop or a single-stranded recognition sequence. These molecules are able to cleave (preferably, repeatedly cleave) separate 15 RNA or DNA molecules in a nucleotide base sequence specific manner. Such molecules can also act to cleave intramolecularly if that is desired. Such enzymatic molecules can be targeted to virtually any RNA transcript.

20 By "L-nucleotide" is meant a nucleotide having the opposite rotatory dispersion spectra to their naturally occurring D-enantiomers (Rosanoff, *supra*). Enantiomers as used herein is meant to indicate the mirror images of each other, as defined by Jacques *et al.*, 1991, *Enantiomers, Racemates, and Resolutions*, pp 3, Krieger Publishing Co., Florida, USA.

25 Jacques *et al.*, 1991, *Enantiomers, Racemates, and Resolutions*, pp 3, Krieger Publishing Co., Florida, USA, define chirality, racemates and enantiomers. They state on pages 3-4 that-

30 "Chirality is a concept well known to organic chemists and, indeed, to all chemists concerned in any way with structure. It has numerous implications ranging from those affecting physical properties of matter to those related to biological mechanisms. These implications extend far beyond the borders of "pure" chemistry....

The geometric property that is responsible for the nonidentity of an object with its mirror image is called *chirality*. A *chiral* object may exist in two *enantiomeric* forms which are mirror images of one another. Such forms lack *inverse symmetry elements*, that is, a center, a plane, and an improper axis of symmetry. Objects that possess one or more of these inverse symmetry elements are superposable on their mirror images; they are *achiral*. All objects necessarily belong to one of these categories; a hand, a spiral staircase, and a snail shell are all chiral, while a cube and a sphere are achiral.

.....All of the foregoing definitions remain valid at the molecular level; there are achiral as well as chiral molecules. The latter exist in two *enantiomeric* forms (the adjective *enantiomeric* is more generally applied to macroscopic objects). The term *enantiomer* is used to designate either a single molecule, a *homochiral collection* of molecules, or even a *heterochiral collection* that contains an excess of one enantiomer and whose composition is defined by its enantiomeric purity *p*, or the *enantiomeric excess* *e.e.* which is equivalent to *p*.

The oldest known manifestation of molecular chirality is the *optical activity*, or *rotatory power*, the property that is exhibited by the rotation of the plane of polarization of light. The two enantiomers of a given compound have rotatory powers of equal absolute value but of opposite *sign*, or *sense*. One is *positive*, or *dextrorotatory*, while the other is *negative*, or *levorotatory*. The absolute designations of sign are arbitrary inasmuch as they are wavelength, temperature, and solvent dependent, but the relative designations are always valid. That is, a given enantiomer may be (+) at one wavelength and (—) at another. The other enantiomer will always have the opposite

sign at the corresponding wavelength. While we shall use as often as possible the (+) and (—) symbols to designate a pair of enantiomers, we shall occasionally employ the letters d and l or D and L for convenience.

5 ....The *absolute configuration* of a chiral substance is known when an enantiomeric structure can be assigned to an optically active sample of a given sign..... Recall that absolute configurations are designated by means of an alphabetic symbolism (R,S for *rectus* and *sinister*) whose application is determined by the rules of Cahn, Ingold, and Prelog. However, 10 the D and L descriptors of Rosanoff are still used for carbohydrates. Care should be exercised so as not to confuse these with the sign of the optical activity." (emphasis added)

15 Tazawa *et al.*, 1970, *Biochemistry*, 3499, described the synthesis of di-nucleotides with L-adenosine residues. They also reported that L-adenosine dimers are "completely" or "extremely" resistant to cleavage by spleen and snake venom phosphodiesterase enzymes.

20 Ashley, 1992, *J. Am. Chem. Soc.*, 114, 9731, RNA molecules composed entirely of L-ribonucleotides {(L)-RNA} can interact stably with a complementary (D)-RNA and poorly with a complementary (D)-DNA. He also mentions in the paper that (L)-RNA is "resistant to both purified ribonuclease A and total cell extracts of L-cells."

25 Klubmann *et al.*, 1996, *Nature Biotech.*, 14, 1112; Nolte *et al.*, 1996, *Nature Biotech.*, 14, 1116, describe a method of selecting L-oligonucleotide aptamers capable of binding D-adenosine and L-arginine ligands.

30 Schumacher and Kim, International PCT Publication No. WO 96/34879, describe a method of identifying "macromolecules (peptides, oligonucleotides, sugar and macromolecular complexes, such as RNA-protein complexes, protein-lipid complexes), which are not of the natural handedness (not of the chirality as they occur in nature or as wildtype molecule) and which are ligands for other chiral macromolecules." The

publications cited above and elsewhere in the application, describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications including the L-nucleotide substitution and the like into ribozymes without inhibiting catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the nucleic acid catalysts of the instant invention.

By the phrase "nucleic acid catalyst" is meant a nucleic acid molecule capable of catalyzing a variety of reactions including the ability to repeatedly cleave other separate nucleic acid molecules (endonuclease activity) in a nucleotide base sequence-specific manner. Such a molecule with endonuclease activity may have complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity that specifically cleaves RNA or DNA in that target. That is, the nucleic acid molecule with endonuclease activity is able to intramolecularly or intermolecularly cleave RNA or DNA and thereby inactivate a target RNA or DNA molecule. This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA or DNA to allow the cleavage to occur. 100% complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention. The nucleic acids may be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity.

By "nucleic acid molecule" as used herein is meant a molecule comprising nucleotides. The nucleic acid can be composed of modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof.

By "complementarity" is meant a nucleic acid that can form hydrogen

bond(s) with other RNA sequence by either traditional Watson-Crick or other non-traditional types (for example, Hoogsteen type) of base-paired interactions.

In preferred embodiments of this invention, the enzymatic nucleic acid molecule is formed in a hammerhead or hairpin motif, but may also be formed in the motif of a hepatitis delta virus (HDV), group I intron, RNaseP RNA (in association with an RNA guide sequence) or *Neurospora* VS RNA. Examples of such hammerhead motifs are described by Rossi *et al.*, 1992, *Aids Research and Human Retroviruses* 8, 183, of hairpin motifs by Hampel *et al.*, EP0360257, Hampel and Tritz, 1989 *Biochemistry* 28, 4929, and Hampel *et al.*, 1990 *Nucleic Acids Res.* 18, 299, and an example of the hepatitis delta virus motif is described by Perrotta and Been, 1992 *Biochemistry* 31, 16; of the RNaseP motif by Guerrier-Takada *et al.*, 1983 *Cell* 35, 849 and Forster and Altman, 1990 *Science* 249, 783, *Neurospora* VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990 *Cell* 61, 685-696; Saville and Collins, 1991 *Proc. Natl. Acad. Sci. USA* 88, 8826-8830; Guo and Collins, 1995 *EMBO J.* 14, 368) and of the Group I intron by Cech *et al.*, U.S. Patent 4,987,071. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule with endonuclease activity of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.

The invention provides a method for producing a class of enzymatic cleaving agents which exhibit a high degree of specificity for the target, such as RNA of a desired target. The enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of a target such that specific treatment of a disease or condition can be provided with a single enzymatic nucleic acid. Such enzymatic nucleic acid molecules can be delivered exogenously to specific cells as required. In the preferred

hammerhead motif the small size (less than 60 nucleotides, preferably between 30-40 nucleotides in length) of the molecule allows the cost of treatment to be reduced compared to other ribozyme motifs.

Therapeutic ribozymes must remain stable within cells until translation of the target mRNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, ribozymes must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677; incorporated by reference herein) have expanded the ability to modify ribozymes to enhance their nuclease stability. The majority of this work has been performed using hammerhead ribozymes (reviewed in Usman and McSwiggen, 1995 *supra*) and can be readily extended to other catalytic nucleic acid motifs.

By "enzymatic portion" is meant that part of the ribozyme essential for cleavage of an RNA substrate.

By "substrate binding arm" is meant that portion of a ribozyme which is complementary to (*i.e.*, able to base-pair with) a portion of its substrate. Generally, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 may be base-paired. Such arms are shown generally in Figures 1a as discussed below. That is, these arms contain sequences within a ribozyme which are intended to bring ribozyme and target RNA together through complementary base-pairing interactions; *e.g.*, ribozyme sequences within stems I and III of a standard hammerhead ribozyme make up the substrate-binding domain (see Figure 1).

In a preferred embodiment, the enzymatic nucleic acid molecules are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to smooth muscle cells. The RNA or RNA complexes can be locally administered to relevant tissues through the use of a catheter, infusion pump or stent, with or without their incorporation in biopolymers. Using the methods described herein, other enzymatic nucleic

acid molecules that cleave target nucleic acid may be derived and used as described above. Specific examples of nucleic acid catalysts of the instant invention are provided below in the Tables and figures.

Sullivan, *et al.*, *supra*, describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Sullivan *et al.*, *supra* and Draper *et al.*, *supra* which have been incorporated by reference herein.

By "consists essentially of" is meant that the active ribozyme contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind target nucleic acid molecules such that cleavage at the target site occurs. Other sequences may be present which do not interfere with such cleavage.

Thus, in one aspect, the invention features ribozymes that inhibit gene expression and/or cell proliferation. These chemically or enzymatically synthesized nucleic acid molecules contain substrate binding domains that bind to accessible regions of specific target nucleic acid molecules. The nucleic acid molecules also contain domains that catalyze the cleavage of target. Upon binding, the enzymatic nucleic acid molecules cleave the target molecules, preventing for example, translation and protein accumulation. In the absence of the expression of the target gene, cell

proliferation, for example, is inhibited.

By "patient" is meant an organism which is a donor or recipient of explanted cells or the cells themselves. "Patient" also refers to an organism to which enzymatic nucleic acid molecules can be administered. Preferably, 5 a patient is a mammal or mammalian cells. More preferably, a patient is a human or human cells.

The novel nucleoside analogs of the instant invention and/or the polynucleotides comprising these analogs are added directly to a cell, or can be complexed with cationic lipids, packaged within liposomes, or otherwise 10 delivered to target cells. The nucleosides, nucleic acid or nucleic acid complexes can be locally administered to relevant tissues *ex vivo*, or *in vivo* through injection, infusion pump or stent, with or without their incorporation 15 in biopolymers.

By "enzymatic portion" is meant that part of the ribozyme essential for 15 cleavage of an RNA substrate.

By "substrate binding arm" is meant that portion of a ribozyme which 20 is complementary to (*i.e.*, able to base-pair with) a portion of its substrate. Generally, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 may be base-paired. Such arms are 25 shown generally in Figures 1-3 as discussed below. That is, these arms contain sequences within a ribozyme which are intended to bring ribozyme and target RNA together through complementary base-pairing interactions; *e.g.*, ribozyme sequences within stems I and III of a standard hammerhead ribozyme make up the substrate-binding domain (see Figure 1).

By "oligonucleotide" or "polynucleotide" as used herein, is meant a 25 molecule comprising two or more nucleotides.



By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, uracil joined to the 1' carbon of  $\beta$ -D-ribo-furanose.

By "modified nucleoside" is meant any nucleotide base which 30 contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate.

Oligonucleotide conjugates with different types of biologically interesting macromolecules or reporter groups are useful as experimental tools. A majority of the methods known in the art for the chemical synthesis of such conjugates are based either on post-synthetic attachment of the 5 molecule of interest to the 3'- and/or 5'-end of oligonucleotides using appropriate spacer, or incorporation of the sugar, base and/or backbone-modified, monomeric nucleoside units into oligonucleotides during chemical synthesis. However, these methods have several disadvantages such as low yields and tedious synthesis schemes. To avoid these problems it is 10 necessary to use unique functional groups both in the oligonucleotides and in the molecule to be attached. These functional groups should be able to react quantitatively, under mild conditions and preferably in water solution. The main idea here is to design a nucleoside monomeric unit 15 (phosphoramidite) bearing a unique functional group, which can be further used as a tether for conjugating any molecule of interest.


Formation of oximes (interaction of aldehydes or ketones with hydroxylamines) or oxyamides (interaction of carboxylic acids with hydroxylamines) seems to be the organic reactions of choice which will meet the above requirements (Sandler, S.R.; Karo, W *Organic Functional Group Preparation* vol. III, ed. Wasserman H.H., Academic Press, Inc., 1989, pp 20 378-523).

In a preferred embodiment, an oligonucleotide would bear one or more hydroxylamino functionalities attached directly to the monomeric unit or through the use of an appropriate spacer. Since oligonucleotides have 25 neither aldehyde nor hydroxylamino groups, the formation of an oxime would occur selectively using oligo as a polymeric template. This approach would facilitate the attachment of practically any molecule of interest (peptides, polyamines, coenzymes, oligosaccharides, lipids, etc.) directly to the oligonucleotide using either aldehyde or carboxylic function in the molecule 30 of interest.

**Scheme 1. Post synthetic Oxime Bond Formation****Scheme 2. Chemical Ligation of Oligonucleotides****Advantages of oxime bond formation:**

- 5     • The oximation reaction proceeds in water
- Quantitative yields
- Hydrolytic stability in a wide pH range (5 - 8)
- The amphoteric nature of oximes allows them to act either as weak acids or weak bases.
- 10    • Oximes exhibit a great tendency to complex with metal ions

In yet another preferred embodiment, the aminoxy "tether" in oligonucleotides, such as a ribozyme, is reacted with different compounds bearing carboxylic groups (e.g. aminoacids, peptides, "cap" structures ,etc.) resulting in the formation of oxyamides as shown below.

**Scheme 3. Post synthetic oxyamide bond formation**

In a preferred embodiment the invention features a process for the synthesis of a 2'-O-amino nucleoside, such as 2'-O-amino adenosine, 2'-O-amino guanosine, 2'-O-amino cytidine, 2'-O-amino uridine and others, comprising the steps of: a) contacting a 3' and 5'-protected arabino nucleoside with sulfonylating reagent, such as tri-fluoromethane sulfonic anhydride, tri-fluoromethane sulfonic chloride and others, under conditions suitable for the formation of 3' and 5'-protected 2'-arabino sulfonyl nucleoside; b) displacement of the sulfonyl group from said 2'-arabino sulfonyl nucleoside with *N*-hydroxy-phthalimide in the presence of a strong organic base, such as 1,8-diazabicyclo(5.4.0)undec-7-ene and the like, under conditions suitable for the formation of 3' and 5'-protected 2'-O-*N*-phthaloyl ribonucleoside; c) deprotection of said *N*-phthaloyl ribonucleoside with a fluoride containing reagent, such as tetrabutylammonium fluoride, triethylamine trihydrofluoride and the like, under conditions suitable for the formation of 2'-O-*N*-phthaloyl ribonucleoside; and d) contacting said 2'-O-*N*-phthaloyl ribonucleoside with a reagent selected from a group consisting of alkylamine (such as methylamine, ethylamine, butylamine and the like), hydrazine, *N*-phenyl hydrazine and *N*-alkylhydrazine (such as *N*-methylhydrazine and the like), under conditions suitable for the formation of said 2'-O-amino nucleoside.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

25

Description of the Preferred Embodiments

The drawings will first briefly be described.

Drawing:

Figure 1 is a diagrammatic representation of the hammerhead ribozyme domain known in the art. Stem II can be  $\geq$  2 base-pair long. Each N is independently any base or non-nucleotide as used herein.

5       Figure 2a is a diagrammatic representation of the hammerhead ribozyme domain known in the art; Figure 2b is a diagrammatic representation of the hammerhead ribozyme as divided by Uhlenbeck (1987, *Nature*, 327, 596-600) into a substrate and enzyme portion; Figure 2c is a similar diagram showing the hammerhead divided by Haseloff and Gerlach 10 (1988, *Nature*, 334, 585-591) into two portions; and Figure 2d is a similar diagram showing the hammerhead divided by Jeffries and Symons (1989, *Nucl. Acids. Res.*, 17, 1371-1371) into two portions.

15       Figure 3 is a diagrammatic representation of the general structure of a hairpin ribozyme. Helix 2 (H2) is provided with at least 4 base pairs (*i.e.*, n is 1, 2, 3 or 4) and helix 5 can be optionally provided of length 2 or more bases (preferably 3 - 20 bases, *i.e.*, m is from 1 - 20 or more). Helix 2 and helix 5 may be covalently linked by one or more bases (*i.e.*, r is  $\geq$  1 base). Helix 1, 4 or 5 may also be extended by 2 or more base pairs (*e.g.*, 4 - 20 base pairs) to stabilize the ribozyme structure, and preferably is a protein 20 binding site. In each instance, each N and N' independently is any normal or modified base and each dash represents a potential base-pairing interaction. These nucleotides may be modified at the sugar, base or phosphate. Complete base-pairing is not required in the helices, but is preferred. Helix 1 and 4 can be of any size (*i.e.*, o and p is each 25 independently from 0 to any number, *e.g.*, 20) as long as some base-pairing is maintained. Essential bases are shown as specific bases in the structure, but those in the art will recognize that one or more may be modified chemically (abasic, base, sugar and/or phosphate modifications) or replaced with another base without significant effect. Helix 4 can be formed from two 30 separate molecules, *i.e.*, without a connecting loop. The connecting loop

when present may be a ribonucleotide with or without modifications to its base, sugar or phosphate. "q" is  $\geq 2$  bases. The connecting loop can also be replaced with a non-nucleotide linker molecule. H, refers to bases A, U or C. Y refers to pyrimidine bases. "—" refers to a chemical bond.

5       Figure 4 is a representation of the general structure of the hepatitis delta virus ribozyme domain known in the art. Each N is independently any base or non-nucleotide as used herein.

Figure 5 is a representation of the general structure of the self-cleaving VS RNA ribozyme domain.

10      Figure 6 is a diagrammatic representation of a few of the novel nucleoside analogs of the instant invention. 1, 3-( $\beta$ -D-Ribofuranosyl)-pyridin-2-one; 2, 5-( $\beta$ -D-Ribofuranosyl)-pyridin-2-one; 3, 5-( $\beta$ -D-Ribofuranosyl)-2-bromopyridine; 4, 5-( $\beta$ -D-Ribofuranosyl)-2-aminopyridine; 5, 3-( $\beta$ -D-Ribofuranosyl)-2-fluoropyridine; 6, 3-( $\alpha$ -D-Ribofuranosyl)-2-fluoropyridine.

15      Figure 7 is a scheme for the synthesis of 5-( $\beta$ -D-Ribofuranosyl)-pyridin-2-one (2 in Figure 6) and 5-( $\beta$ -D-Ribofuranosyl)-2-bromopyridine (3 in Figure 6 and 11 in Figure 7) monomers.

20      Figure 8 describes two schemes for the synthesis of 3-( $\beta$ -D-Ribofuranosyl)-pyridin-2-one (1 in Figure 6 and 13 in Figure 8B) and 3-( $\beta$ -D-Ribofuranosyl)-2-fluoropyridine (5 in Figure 6 and 12 in Figure 8B) monomers.

25      Figure 9 is a scheme for the synthesis of 1-(5-O-Dimethoxytrityl-2-O-tert-butyldimethylsilyl-3-O-2-cyanoethyl-N,N-diisopropylaminophosphoramidite- $\beta$ -D-ribofuranosyl)-1,4-dihydro-pyrimidine-4-one.

Figure 10 is a scheme for the synthesis of 1-(5-O-Dimethoxytrityl-2-O-tert-butyldimethylsilyl-3-O-2-cyanoethyl-N,N-diisopropylaminophosphoramidite- $\beta$ -D-Ribofuranosyl)-1,4-dihydro-pyrimidine-2-one.

30      Figure 11 is a scheme for the synthesis of 5'-O-Dimethoxytrityl-2'-O-tert-Butyldimethylsilyl-O<sup>4</sup>-Diphenylcarbamoyl-3-Deaza Uridine 3'-(2-

Cyanoethyl N,N-diisopropylphosphoramidite).

Figure 12 is a scheme for the synthesis of 5'-O-dimethoxytrityl-2'-O-tert-butyldimethylsilyl-O<sup>4</sup>-diphenylcarbamoyl-3-deaza cytidine 3'-(2-Cyanoethyl N,N-diisopropylphosphoramidite).

5 Figure 13 is a scheme for the synthesis of 2-O-*t*-Butyldimethylsilyl-5-O-Dimethoxytrityl-3-O-(2-Cyanoethyl-N,N-diisopropylphosphoramidite)- $\beta$ -D-ribofuranosylindole.

10 Figure 14 is a scheme for the synthesis of 2-O-*t*-Butyldimethylsilyl-5-O-Dimethoxytrityl-3-O-(2-Cyanoethyl-N,N-diisopropylphosphoramidite)- $\beta$ -D-ribofuranosylbenzimidazole.

Figure 15 is a scheme for the synthesis of 3-( $\beta$ -D-Ribofuranosyl)-Pyridine-2-(4-Nitrophenylethyl)-One and 5-( $\beta$ -D-Ribofuranosyl)-Pyridine-2-(4-Nitrophenylethyl)-One Phosphoramidite.

15 Figure 16 is a scheme for the synthesis of 2'-O-amino pyrimidine nucleoside and phosphoramidite.

Figure 17 is a scheme for the synthesis of 2'-O-amino adenosine nucleoside and phosphoramidite.

20 Figure 18 is a scheme for the synthesis of 2'-O-amino guanosine nucleoside and phosphoramidite.

Figure 19 is a diagrammatic representation of hammerhead ribozymes substituted with 2'-O-amino groups at various positions (A). (B) shows the rates of RNA cleavage reaction catalyzed by the ribozymes of 9 A.

25 Figure 20 shows the general structure of a D-nucleotide and a L-nucleotide.

Figure 21 shows a scheme for the phosphoramidite synthesis of L-ribonucleosides (Scheme 1).

Figure 22 shows a scheme for the phosphoramidite synthesis of L-ribonucleosides using 5'-O-silyl protection (Scheme 2).

30 Figure 23 shows: A) a scheme for the synthesis of L-2'-amino-2'-deoxy-pyrimidine phosphoramidites. B) a scheme for the synthesis of L-2'-

amino-2'-deoxy-purine phosphoramidites.

Figure 24 is a diagrammatic representation of a hammerhead ribozyme-substituted with L-nucleotides.

Figure 25 is a graphical representation of RNA cleavage reaction  
5 catalyzed by hammerhead ribozymes with L-nucleotide substitutions.

### Synthesis of Polynucleotides

Nucleic acid molecules, for example having an endonuclease enzymatic activity are able to repeatedly cleave other separate RNA molecules in a nucleotide base sequence-specific manner. Such enzymatic RNA molecules can be targeted to virtually any RNA transcript, and efficient cleavage achieved *in vitro* (Zaug et al., 324, *Nature* 429 1986 ; Kim et al., 10 84 *Proc. Natl. Acad. Sci. USA* 8788, 1987; Haseloff and Gerlach, 334 *Nature* 585, 1988; Cech, 260 *JAMA* 3030, 1988; and Jefferies et al., 17 *Nucleic 15 Acids Research* 1371, 1989). Because of their sequence-specificity, *trans*-cleaving ribozymes show promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 *Ann. Rep. Med. Chem.* 30, 285-294; Christoffersen and Marr, 1995 *J. Med. Chem.* 38, 2023-2037). Ribozymes can be designed to cleave specific RNA targets within the background of 20 cellular RNA. Such a cleavage event renders the mRNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited.

Seven basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds in *trans* (and thus can cleave other RNA molecules) under 25 physiological conditions. Table I summarizes some of the characteristics of these ribozymes. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the 30 enzymatic nucleic acid first recognizes and then binds a target RNA through

complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is 5 released from that RNA to search for another target and can repeatedly bind and cleave new targets.

The enzymatic nature of a ribozyme is advantageous over other technologies, since the effective concentration of ribozyme necessary to effect a therapeutic treatment is lower than that of an antisense 10 oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding, but also on the mechanism by which the 15 molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base-pairing. Thus, it is thought 20 that the specificity of action of a ribozyme is greater than that of antisense oligonucleotide binding the same RNA site.

In one of the preferred embodiments of the inventions herein, the enzymatic nucleic acid molecule is formed in a hammerhead or hairpin motif, but may also be formed in the motif of a hepatitis  $\delta$  virus, group I intron, 25 group II intron or RNaseP RNA (in association with an RNA guide sequence) or *Neurospora* VS RNA (figure 4, 5). Examples of such hammerhead motifs are described by Dreyfus, *supra*, Rossi *et al.*, 1992, *AIDS Research and Human Retroviruses* 8, 183; of hairpin motifs by Hampel *et al.*, EP0360257, Hampel and Tritz, 1989 *Biochemistry* 28, 4929, Feldstein *et al.*, 1989, *Gene* 30 82, 53, Haseloff and Gerlach, 1989, *Gene*, 82, 43, and Hampel *et al.*, 1990 *Nucleic Acids Res.* 18, 299; of the hepatitis  $\delta$  virus motif is described by

Perrotta and Been, 1992 *Biochemistry* 31, 16; of the RNaseP motif by Guerrier-Takada *et al.*, 1983 *Cell* 35, 849; Forster and Altman, 1990, *Science* 249, 783; Li and Altman, 1996, *Nucleic Acids Res.* 24, 835; *Neurospora* VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990 *Cell* 61, 685-696; Saville and Collins, 1991 *Proc. Natl. Acad. Sci. USA* 88, 8826-8830; Collins and Olive, 1993 *Biochemistry* 32, 2795-2799; Guo and Collins, 1995, *EMBO J.* 14, 363); Group II introns are described by Griffin *et al.*, 1995, *Chem. Biol.* 2, 761; Michels and Pyle, 1995, *Biochemistry* 34, 2965; Pyle *et al.*, International PCT Publication No. WO 10 96/22689; and of the Group I intron by Cech *et al.*, U.S. Patent 4,987,071. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.

20 Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs (e.g., antisense oligonucleotides, hammerhead or the hairpin ribozymes) are used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of the mRNA structure.

25 Synthesis of polynucleotides greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small enzymatic nucleic acid motifs (e.g., of the hammerhead or the hairpin structure) are used for exogenous delivery. The simple structure of these molecules increases the ability of the enzymatic nucleic acid to invade targeted regions of the mRNA structure.

30 RNA molecules, such as the ribozymes are chemically synthesized. The method of synthesis used follows the procedure for normal RNA

synthesis as described in Usman *et al.*, 1987 *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990 *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684 and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. Small scale synthesis were conducted on a 394 Applied Biosystems, Inc. synthesizer using a modified 2.5  $\mu$ mol scale protocol with a 5 min coupling step for alkylsilyl protected nucleotides and 2.5 min coupling step for 2'-O-methylated nucleotides. Table 2 outlines the amounts, and the contact times, of the reagents used in the synthesis cycle. A 6.5-fold excess (163  $\mu$ L of 0.1 M = 16.3  $\mu$ mol) of phosphoramidite and a 24-fold excess of S-ethyl tetrazole (238  $\mu$ L of 0.25 M = 59.5  $\mu$ mol) relative to polymer-bound 5'-hydroxyl was used in each coupling cycle. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, were 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer: detritylation solution was 2% TCA in methylene chloride (ABI); capping was performed with 16% *N*-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution was 16.9 mM  $I_2$ , 49 mM pyridine, 9% water in THF (Millipore). B & J Synthesis Grade acetonitrile was used directly from the reagent bottle. S-Ethyl tetrazole solution (0.25 M in acetonitrile) was made up from the solid obtained from American International Chemical, Inc.

Deprotection of the RNA was performed as follows. The polymer-bound oligoribonucleotide, trityl-off, was transferred from the synthesis column to a 4mL glass screw top vial and suspended in a solution of methylamine (MA) at 65 °C for 10 min. After cooling to -20 °C, the supernatant was removed from the polymer support. The support was washed three times with 1.0 mL of EtOH:MeCN:H<sub>2</sub>O/3:1:1, vortexed and the supernatant was then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, were dried to a white powder.

5 The base-deprotected oligoribonucleotide was resuspended in anhydrous TEA•HF/NMP solution (250  $\mu$ L of a solution of 1.5mL *N*-methyl-pyrrolidinone, 750  $\mu$ L TEA and 1.0 mL TEA•3HF to provide a 1.4M HF concentration) and heated to 65°C for 1.5 h. The resulting, fully deprotected, oligomer was quenched with 50 mM TEAB (9 mL) prior to anion exchange desalting.

10 For anion exchange desalting of the deprotected oligomer, the TEAB solution was loaded onto a Qiagen 500® anion exchange cartridge (Qiagen Inc.) that was prewashed with 50 mM TEAB (10 mL). After washing the loaded cartridge with 50 mM TEAB (10 mL), the RNA was eluted with 2 M TEAB (10 mL) and dried down to a white powder.

15 Inactive hammerhead ribozymes were synthesized by substituting a U for G<sub>5</sub> and a U for A<sub>14</sub> (numbering from (Hertel, K. J., et al., 1992, *Nucleic Acids Res.*, 20, 3252)).

20 The average stepwise coupling yields were >98% (Wincott et al., 1995 *Nucleic Acids Res.* 23, 2677-2684).

25 Hairpin ribozymes are synthesized either as one part or in two parts and annealed to reconstruct the active ribozyme (Chowrira and Burke, 1992 *Nucleic Acids Res.*, 20, 2835-2840).

30 RNAs are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; See Stinchcomb et al., International PCT Publication No. WO 95/23225, the totality of which is hereby incorporated herein by reference) and are resuspended in water.

35 Various modifications to ribozyme structure can be made to enhance the utility of ribozymes. Such modifications will enhance shelf-life, half-life *in vitro*, stability, and ease of introduction of such ribozymes to the target site, *e.g.*, to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.

Optimizing Ribozyme Activity

Ribozyme activity can be optimized as described by Stinchcomb *et al.*, *supra*. The details will not be repeated here, but include altering the length of the ribozyme binding arms (stems I and III, see Figure 2c), or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see e.g., Eckstein *et al.*, International Publication No. WO 92/07065; Perrault *et al.*, 1990 *Nature* 344, 565; Pieken *et al.*, 1991 *Science* 253, 314; Usman and Cedergren, 1992 *Trends in Biochem. Sci.* 17, 334; Usman *et al.*, International Publication No. WO 93/15187; Rossi *et al.*, International Publication No. WO 91/03162; as well as Sproat, US Patent No. 5,334,711 which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules). Modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements are desired. (All these publications are hereby incorporated by reference herein).

Administration of Polynucleotides

Sullivan *et al.*, PCT WO 94/02595, describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery

and administration are provided in Sullivan *et al.*, *supra* and Draper *et al.*, PCT WO93/23569 which have been incorporated by reference herein.

### Examples

5 The following are non-limiting examples showing the synthesis and activity of the certain compounds of Formula I-V of the instant invention and polynucleotides comprising one or more of these compounds. Those in the art will recognize that certain reaction conditions such as temperatures, pH, 10 ionic conditions, reaction times and solvent conditions described in the following examples are not meant to be limiting and can be readily modified without significantly effecting the synthesis.

#### Example 1: Synthesis of Ribozymes Containing Base-Modified Nucleotides

15 The method of synthesis used follows the procedure for normal RNA synthesis as described in Usman *et al.*, *J. Am. Chem. Soc.* 1987, 109, 7845-7854; Scaringe *et al.*, *Nucleic Acids Res.* 1990, 18, 5433-5441 and Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684 and makes use of common 20 nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end (compounds 4, 9, 13, 17, 22, 23). The average stepwise coupling yields were >98%. These base-modified nucleotides may be incorporated not only into hammerhead ribozymes, but also into hairpin, VS ribozymes, hepatitis delta virus, or Group I or Group II introns. They are, therefore, of general use as replacement motifs in any nucleic acid structure.

#### Example 2: Synthesis of 5-( $\beta$ -D-Ribofuranosyl)-Pyridin-2-one (2)

25 Referring to Figure 7, Pyridin-2-one C-nucleoside 2 (Figure 6) was prepared in 5 steps from 2-(benzyloxy)-5-iodopyridine (3) and D-ribono-1,4-lactone 4 and alternatively, in 7 steps from 2,5-dibromopyridine (7) and D-ribono-1,4-lactone 4. The intermediate 1'-O-Ac derivative 9 was crucial for the successful deoxygenation of hemiacetal 8.

The synthesis of a pyrimidine nucleoside analog **2** which lacks O<sup>2</sup> carbonyl is described herein. These analogs of pyrimidine nucleosides with novel H-bonding patterns could serve as valuable tools for identification of essential intramolecular hydrogen bonding interactions. 2'-Deoxy analog of 5 **1** (Solomon, M.S.; Hopkins, P.B. *Tetrahedron Lett.* 1991, 32, 3297-3300; Solomon, M.S.; Hopkins, P.B. *J. Org. Chem.* 1993, 58, 2232-2243) and **1** is described as a mixture of  $\alpha$  and  $\beta$  anomers (Belmas *et al.*, 1989 *Nucleosides & Nucleotides* 8, 307). The ribo derivative **2** is not known and are described here.

10 In one attempt to synthesize **2** (Figure 7) Applicant converted 2-(benzyloxy)-5-iodopyridine (**3**) (synthesized from 2-bromo-5-iodopyridine (Hama *et al.*, *Bull. Chem. Soc. Jpn.* 1988, 61, 1683-1686) using reducing reagents such as NaH/BnOH/DMF) to 5-lithio derivative by metallation using reagents such as, lithium diazabutylamine (LDA) under suitable conditions 15 such as using a temperature of about -78 °C. Condensation of a protected D-ribonolactone, such as 5-O-*t*-butyldiphenylsilyl-2,3-O-isopropylidene-D-ribonolactone (**4**) with this intermediate (5-lithio derivative) yielded the mixture of  $\alpha$  and  $\beta$  lactols **5** in 1:8 ratio (47% yield). It should be noted that for hemiacetals **5**, **8** and **9**, the prefix  $\alpha$  refers to the position of the glycosidic 20 OH group relative to the configuration at the reference C-atom (C4' in **2**; *i.e.* the pyridyl moiety is in the  $\beta$ -position). The assignments of the anomeric configurations were based on  $\Delta\delta$  values for the isopropylidene Me groups in <sup>1</sup>H NMR spectra. It is known from the previous work (Gudmundsson *et al.*, *Tetrahedron Lett.* 1996, 37, 2365-2368; Dondoni, A.; Schermann, M.-C. *J. Org. Chem.* 1994, 59, 6404-6412) that reductive 1'-deacetoxylation is a 25 much more efficient approach to 1'-deoxygenation than direct reduction of 1'-OH. Unfortunately, acetylation of **5** with Ac<sub>2</sub>O/DMAP/TEA in acetonitrile failed; the major product did not contain acetyl group by <sup>1</sup>H NMR.

30 Reduction of **5** with reducing agents, such as triethylsilane (Et<sub>3</sub>SiH)/BF<sub>3</sub>•Et<sub>2</sub>O in acetonitrile at temperatures such as room temperature yielded an 1:1  $\alpha$ / $\beta$  mixture of C-nucleosides **6** in 21% yield. **6** $\beta$  and **6** $\alpha$  were

easily separated by flash column chromatography using 5-10% gradient of methanol in dichloromethane for elution.

6 $\beta$  was deblocked using reagents such as TBAF to remove the 5'-silyl ether protection followed by the cleavage of isopropylidene group with acid to yield 12 in a good yield ( $^1$ H NMR ( $CD_3)_2CO + D_2O$ ) data for 12:  $\delta$  8.19 (d,  $J_{6,4}=2.4$ , 1H, H6), 7.79 (dd,  $J_{4,3}=8.4$ ,  $J_{4,6}=2.4$ , 1H, H4), 6.80 (d,  $J_{3,4}=8.4$ , 1H, H3), 5.37 (s, 2H,  $CH_2Ph$ ), 4.64 (d,  $J_{1,2}=7.2$ , 1H, H1'), 4.12 (dd,  $J_{3',2}=5.4$ ,  $J_{3',4}=3.4$ , 1H, H3'), 3.95 (m, 1H, H4'), 3.88 (dd,  $J_{2',1}=7.2$ ,  $J_{2',3}=5.4$ , 1H, H2'), 3.74 (dd,  $J_{5',4}=3.6$ ,  $J_{5',5}=12.0$ , 1H, H5'), 3.69 (dd,  $J_{5',4}=4.2$ ,  $J_{5',5}=12.0$ , 1H, H5").

Compound 12 was obtained by removing the Bzl group using a variety of different approaches, such as cleavage of benzyl ether group of 12 using trimethylsilyl iodide (TMSI) in dichloromethane yielding the free C-nucleoside 2 in a good yield.

Parham and Piccirilli (*J. Org. Chem.* 1977, 42, 257-260) described an unexpected and highly selective halogen-lithium exchange between 2,5-dibromopyridine (7) and *n*-butyllithium at very low temperature (-100 °C), where only 5-bromo substituent was exchanged. Applicant synthesized 2 by an alternative approach starting from 7 and D-ribono-1,4-lactone 4 (Scheme 1). Metallation of 7 at about -100°C in THF and condensation of the resulting lithiated pyridine with protected D-ribono-1,4-lactone 4 at -100 °C afforded the expected hemiacetal 8 (44% yield,  $\alpha/\beta$  1:12) along with two by-products in 6% and 17% yield, respectively.

Procedure for the preparation of 8: 2,5-dibromopyridine 7 (1.75 g, 7.4 mmol) was dissolved in dry THF (46 ml) under argon and the solution was cooled to -100 °C. 1.6 M *n*-BuLi in hexanes (5.09 ml, 8.14 mmol) was added dropwise over 5 min and the solution stirred at -100 °C for 30 min. The solution of D-ribono-1,4-lactone 4 (3 g, 7 mmol) in dry THF (10 ml) was added dropwise over 5 min and the mixture warmed up to rt over 40 min. It was stirred additional 20 min at rt, then quenched with saturated aq.  $NH_4Cl$ . The mixture was extracted with ether, organic layer washed with

brine, dried and evaporated to a syrup. Flash column chromatography using 3-15% gradient of ethyl acetate in hexanes eluted first **8** (1.8 g, 44%), followed by the slower product (0.23 g, 6%). At the end the slowest material eluted (0.7 g, 17%).

5 All three products exhibited sugar <sup>1</sup>H NMR signals consistent with the hemiacetal structure. This result demonstrates the selectivity in lithiation of **7**, but the formation of other products suggests that competing halogen-lithium exchange occurred, too. Deoxygenation of **8** using the same procedure as for reduction of **5** yielded, similarly as in the case of **5**, an 1:1  
10 mixture of  $\alpha$ / $\beta$  nucleosides in a low yield. On the other hand, acetylation of **8** proceeded in a quantitative yield to give **9** (only  $\beta$ -anomer was obtained). Reduction of **9** using Et<sub>3</sub>SiH/BF<sub>3</sub>•Et<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub> at 0 °C-rt proceeded in 82%  
15 yield but again without selectivity (10 $\alpha$ /10 $\beta$  1:1). The anomeric assignments were based on, besides  $\Delta\delta$  of methyl groups, on the well known upfield shift of the 1'-H signal for the  $\beta$ -anomer compared to the  $\alpha$ -anomer (Tam *et al.*, J. Org. Chem. 1979, 44, 4854-4862; Sokolova *et al.*, Carbohydr. Res. 1981, 93, 19-34). 10 $\beta$  was deprotected to **11** in two steps (1 M TBAF, followed by refluxing 80% acetic acid). Derivative **11** was highly resistant to displacement of 2-bromo substituent with methoxide and benzylate; only  
20 KH/BnOH/DMF at 140 °C afforded **12** in a good yield, identical in every aspect with the compound synthesized from 2-(benzyloxy)-5-iodopyridine **3**. This comparison proved unequivocally that 5-pyridyl regiosiomer **8** was the main product obtained from 2,5-dibromopyridine **7**.

25 *Synthesis of 5-( $\alpha$ -D-Ribofuranosyl)-pyridin-2-one:* Treatment of **6 $\alpha$**  with TBAF to remove the 5'-silyl ether protection followed by the cleavage of isopropylidene group with acid followed by cleavage of benzyl ether group using trimethylsilyl iodide (TMSI) in dichloromethane will yield 5-( $\alpha$ -D-Ribofuranosyl)-pyridin-2-one in a good yield.

30 *Synthesis of 5-( $\alpha$ -D-Ribofuranosyl)-2-bromopyridine:* Treatment of **10 $\alpha$**  with TBAF to remove the 5'-silyl ether protection followed by the cleavage of isopropylidene group with acid will yield 5-( $\alpha$ -D-Ribofuranosyl)-

2-bromopyridine in good yield.

*Synthesis of 5-( $\beta$ -D-Ribofuranosyl)-2-aminopyridine:* 2-Bromo derivative **11** (580 mg, 2 mmol) was placed in a steel autoclave and the autoclave purged with a continuous stream of Ar. CuI (720 mg, 2 eq.) was added and the autoclave cooled in a Dewar vessel (CO<sub>2</sub>-isopropanol). Purging over the apparatus with Ar was continued while NH<sub>3</sub> was condensed in the autoclave (ca. 15 ml). The autoclave was then quickly closed, the mixture allowed to warm to rt, placed in a heated oil bath at 115 °C and stirred for 24 h. The autoclave was then cooled as before, opened, warmed up to rt and NH<sub>3</sub> evaporated. Then, the dark mixture was dissolved in MeOH, filtered and evaporated to a syrup. Column chromatography (silica gel, MeOH/CHCl<sub>3</sub>) yielded 5-( $\beta$ -D-Ribofuranosyl)-2-aminopyridine (**4** in Figure 6) (235 mg, 52%).

*Synthesis of 5-( $\alpha$ -D-Ribofuranosyl)-2-aminopyridine:* 5-( $\alpha$ -D-Ribofuranosyl)-2-bromopyridine (580 mg, 2 mmol) was placed in a steel autoclave and the autoclave purged with a continuous stream of Ar. CuI (720 mg, 2 eq.) was added and the autoclave cooled in a Dewar vessel (CO<sub>2</sub>-isopropanol). Purging over the apparatus with Ar was continued while NH<sub>3</sub> was condensed in the autoclave (ca. 15 ml). The autoclave was then quickly closed, the mixture allowed to warm to rt, placed in a heated oil bath at 115 °C and stirred for 24 h. The autoclave was then cooled as before, opened, warmed up to rt and NH<sub>3</sub> evaporated. Then, the dark mixture was dissolved in MeOH, filtered and evaporated to a syrup. Column chromatography (silica gel, MeOH/CHCl<sub>3</sub>) yielded 5-( $\alpha$ -D-Ribofuranosyl)-2-aminopyridine.

Although the two approaches reported herein produced  $\alpha$ / $\beta$  anomers in 1:1 ratio, they represent useful methods for the preparation of larger quantities of C-nucleoside **2** for the synthesis of oligonucleotide building blocks. Both **2** and **11** might display, like other C-nucleosides, pharmaceutically useful biological activities.

**Example 3: Synthesis of 3-( $\beta$ -D-Ribofuranosyl)-2-Fluoropyridine (1) and 3-( $\beta$ -D-Ribofuranosyl)-Pyridin-2-one (5)**

Referring to Figure 8, Pyridin-2-one C-nucleoside 13 (1 in Figure 6) was synthesized by reducing 3 at room temperature followed by a cyclization reaction to yield compounds 5 and 8. Deblocking followed by hydrogenolysis and debenzylation yields compound 13.

Pyridin-2-one C-nucleoside 13 (1 in Figure 6) was prepared in 7 steps from 2-fluoro-3-lithiopyridine (1) and D-ribono-1,4-lactone 2. The successful approach to  $\beta$ -ribofuranosides 12 (5 in Figure 6) and 13 consisted in the reductive opening of furanose ring of hemiacetal 3 followed by intramolecular Mitsunobu cyclization.

The synthesis of a pyrimidine nucleoside analogs 12 and 13 which lack O<sup>4</sup> carbonyl is described herein and can be used for identification of essential intramolecular hydrogen bonding interactions.

The synthesis of 13 as an anomeric mixture is described from 2,4:3,5-di-O-benzylidene-aldehydo-D-ribose and 3-lithio-2-fluoropyridine (Belmans *et al.*, *Nucleosides & Nucleotides* 1989, 8, 307-315). This procedure, however, was inefficient and not amenable to large-scale preparations due to involvement of a ribose dithioacetal during preparation of the key starting material. Besides, 2-fluoropyridine derivative 12 could not be isolated by this route because of the solvolytic displacement of fluorine atom during the acid catalyzed cyclization of open chain precursor.

Referring to Figure 8A, Applicant used a protected D-ribonolactone such as 5-O-*t*-butyldiphenylsilyl-2,3-O-isopropylidene-D-ribonolactone (2) in the condensation with 3-lithio-2-fluoropyridine ( -78 °C, then rt, 18 h, THF) and obtained 1:5  $\alpha$ / $\beta$  mixture of lactols 3 in 63 % yield (Scheme 1). It should be noted that for hemiacetals 3, the prefix  $\alpha$  refers to the position of the glycosidic OH group relative to the configuration at the reference C-atom (C4' in 2; *i.e.* the pyridyl moiety is in the  $\beta$ -position). The assignments of the anomeric configurations were based on  $\Delta\delta$  values for the isopropylidene Me groups in <sup>1</sup>H NMR spectra. All attempts to dehydroxylate 3 using

triethylsilane ( $\text{Et}_3\text{SiH}$ ) in the presence of  $\text{BF}_3 \bullet \text{Et}_2\text{O}$  or TMSOTf in a variety of solvents resulted in poor yields of nucleosides 5. Besides, the desired  $\beta$ -nucleoside was always the minor anomer in the mixture. The anomeric assignments were based on, besides  $\Delta\delta$  of isopropylidene methyl groups, on the well known upfield shift of the 1'-H signal for the  $\beta$ -anomer compared to the  $\alpha$ -anomer.

It was demonstrated that the more efficient and/or selective reduction of 1'-hydroxyl group can be achieved through intermediate 1'-OAc derivative (i.e. 4; Gudmundsson et al., *Tetrahedron Lett.* 1996, 37, 2365; Dondoni et al., *J. Org. Chem.* 1994, 59, 6404-6412). Applicant found that 3 could be acetylated in a quantitative yield using  $\text{Ac}_2\text{O}/\text{TEA}/\text{DMAP}$  in acetonitrile to give 4 (only one isomer was generated, no attempt was made to determine its configuration). Reductive deacetoxylation of 4 with  $\text{Et}_3\text{SiH}/\text{TMSOTf}$  in dichloromethane at 0 °C-rt proceeded efficiently and afforded a good yield of 5 ( $\alpha/\beta$  10:1); when  $\text{Et}_3\text{SiH}$  was a solvent the  $\alpha/\beta$  ratio was 5:1. These results are surprising because under similar reaction conditions the exclusive  $\beta$ -selectivity in the reduction of pyrazine (Liu et al., *Tetrahedron Lett.* 1996, 37, 5325-5328) and imidazo[1,2-a]pyridine lactols (Gudmundsson et al., *Tetrahedron Lett.* 1996, 37, 2365-2368) was reported.

In order to obtain practical quantities of  $\beta$  C-nucleoside Applicant investigated further several different pathways: Mesylation of 3 afforded 1'-O-mesyl derivative 6 in a moderate yield (Scheme 2). Treatment of 6 with LAH did not reduce the sulfonate as reported for 2-pyridine C-nucleosides. The more reactive  $\text{LiEt}_3\text{BH}$  also failed. It is worth noting that preparation of a more reactive 1'-O-Tf derivative failed due to the opening of the furanose ring under triflylation conditions.

Pankiewicz et al., (*J. Org. Chem.* 1988, 53, 3473-3479) reported hydrogenolytic opening of the hemiacetal ring of 6-pyridine lactol derivatives to generate mixtures of *allo* and *altro* isomers. Reaction of 3 with  $\text{NaBH}_4$  proceeded in a quantitative yield to give ca 1:1 ratio of *allo/altro* 7. These

epimers were not separated but treated under standard Mitsunobu conditions [diethyl azodicarboxylate (DEAD)/Ph<sub>3</sub>P/THF, reflux] to give **5** ( $\alpha/\beta$  ratio 1:2) and 3-(2,3-O-isopropylidene-5-O-*t*-butyldiphenylsilyl- $\alpha$ -L-*lyxo*-furanosyl)-2-fluoropyridine (**8**), the latter arising from the competitive formation of 4'-oxyphosphonium intermediate. Yokoyama *et al.*, (*Chem. Lett.* 1994, 265-268) speculated that such an intermediate is formed because of the hydrogen bonding between 1'-OH and the hydrogen acceptor on the 2-pyridyl base. It is worth noting that if Mitsunobu cyclization of **7** was conducted at rt more *lyxo* derivative **8** was obtained than at reflux temperature. This indicates the existence of the hydrogen bond between 1'-OH and fluorine in its close proximity which could be disrupted by increasing the reaction temperature. Recently, an efficient synthesis of imidazole C-nucleosides was reported using similar Mitsunobu cyclization as the key step (Hurusawa *et al.*, *J. Org. Chem.* 1996, 61, 4405-4411). It was difficult to chromatographically separate the mixture of **5** and **8** so it was first 5'-desilylated with TBAF and then fractionated using flash silica gel column chromatography. In a typical procedure **7** (7 g, 13 mmol) and Ph<sub>3</sub>P (5.25 g, 20 mmol) are dissolved in THF and the mixture is heated to reflux. DEAD (3.15 ml, 20 mmol) is then added to the refluxing mixture and heating continued for 1 hour. Solvent is removed *in vacuo* and the residue purified by flash column chromatography using 9-11% gradient of ethyl acetate in hexanes for elution. 5.6 g, 83% of the mixture of **5** and **8** was obtained after removal of solvents (see Figure 8B). The above mixture is dissolved in THF (75 ml) and treated with 1 M TBAF in THF (22 ml, 2 eq) for 1 hour. It is then concentrated *in vacuo* and chromatographed on the column of silica gel using 15-70% gradient of ethyl acetate in hexanes for elution.  $\alpha$ -Anomer **10** eluted first (0.56 g, 19%), followed by  $\beta$ -anomer **9** (1.6 g, 54%). *Lyxo* derivative **11** eluted last (0.55 g, 19%).  $\beta$ -anomer **9** was obtained in 45% yield in two steps from **7**, while  $\alpha$ -anomer **10** and *lyxo* derivative **11** were both obtained in 16% yield. **9** was converted into free 2-fluoro nucleoside **12** (mp 134-135 °C, from THF) by boiling in 80% acetic acid and then

converted into 2-(benzyloxy) derivative with BnOK (<sup>1</sup>H NMR (CD<sub>3</sub>OD) data for **12**:  $\delta$  8.19 (m, 1H, H6), 8.11 (m, 1H, H4), 7.32 (m, 1H, H5), 4.98 (d, J<sub>1',2'</sub>=5.6, 1H, H1'), 4.05-3.96 (m, 3H, H2',H3',H4'), 3.84 (dd, J<sub>5',4'</sub>=3.0, J<sub>5',5'</sub>=12.0, 1H, H5'), 3.73 (dd, J<sub>5',4'</sub>=4.6, J<sub>5',5'</sub>=12.0, 1H, H5"). Catalytic 5 hydrogenolysis of benzyl group (H<sub>2</sub>, Pd-C) simultaneously cleaved C1'-O4' bond. Debenzylation was carried out successfully with trimethylsilyl iodide (TMSI) to afford 3-( $\beta$ -D-ribofuranosyl)pyridin-2-one (**13**) in 83% yield as a syrup [UV(MeOH)  $\lambda_{max}$  302 nm].  $\alpha$ -Anomer **10** was deprotected in the same manner as **9** to give **14** (mp 173-174 °C, from CH<sub>2</sub>Cl<sub>2</sub>; <sup>1</sup>H NMR (CD<sub>3</sub>OD) data for **14**:  $\delta$  8.12-8.06 (m, 2H, H6,H4), 7.31 (m, 1H, H5), 5.26 (d, J<sub>1',2'</sub>=2.8, 1H, H1'), 4.35-4.25 (m, 2H, H2',H3'), 4.04 (m, 1H, H4'), 3.88 (dd, J<sub>5',4'</sub>=2.6, J<sub>5',5'</sub>=11.8, 1H, H5'), 3.68 (dd, J<sub>5',4'</sub>=4.6, J<sub>5',5'</sub>=11.8, 1H, H5"). An attempt to 10 displace fluorine in **14** with benzylate yielded the anhydro derivative **15** in a quantitative yield [mp 195-196 °C, UV(MeOH)  $\lambda_{max}$  286 nm; <sup>1</sup>H NMR (CD<sub>3</sub>)<sub>2</sub>CO data for **15**:  $\delta$  8.10 (dd, J<sub>6,5'</sub>=5.2, J<sub>6,4'</sub>=1.6, 1H, H6), 7.80 (dd, J<sub>4,5'</sub>=7.3, J<sub>4,6'</sub>=1.6, 1H, H4,), 6.95 (dd, J<sub>5,6'</sub>=5.2, J<sub>5,4'</sub>=7.3, 1H, H5), 5.59 (d, J<sub>1',2'</sub>=6.0, 1H, H1'), 5.36 (d, J<sub>OH,3'</sub>=7.2, 1H, 3'OH), 5.02 (dd, J<sub>2',1'</sub>=6.0, J<sub>2',3'</sub>=5.2, 1H, H2'), 4.64 (t, J<sub>5',OH</sub>=5.4, 1H, OH5'), 3.97 (m, 1H, H3'), 3.62 (dq, J<sub>5',4'</sub>=2.2, J<sub>5',5'</sub>=12.2, 1H, H5'), 3.39 (m, 1H, H5"), 3.22 (m, 1H, H4')]. This unexpected 15 cyclization can be explained by an intramolecular nucleophilic displacement 20 of fluorine by an adjacent 2'-hydroxyl. The structure of **11** was confirmed by NOE experiments in which mutual enhancement was observed between H4' and H3' (6% NOE) and between H4' and H4 (5% NOE).

Applicant has now described useful methods for the synthesis of 25 larger quantities of  $\beta$ -anomers of C-nucleosides **12** an **13** as starting materials for the preparation of building blocks for oligonucleotide synthesis. These analogs are also interesting as potential antiviral and/or anticancer agents.

Example 4: Synthesis of 1-(5-O-Dimethoxytrityl-2-O-tert-butyldimethylsilyl-3-O-2-cyanoethyl-N,N-diisopropylaminophoramidite-β-D-Ribofuranosyl)-1,4-dihydro-pyrimidine-4-one (7)

Referring to Figure 9, 1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-1,4-dihydropyrimidine-4-one (3) was synthesized in accordance with Niedballa *et al.*, *J.Org.Chem.* 1974, 39, 3668-3671. 1-(β-D-Ribofuranosyl)-1,4-dihydropyrimidine-4-one (5) was prepared by standard NaOMe/MeOH deprotection of derivative 3 with nearly quantitative yield. 1-(5-O-Dimethoxytrityl-β-D-Ribofuranosyl)-1,4-dihydropyrimidine-4-one (6) was prepared by standard dimethoxytritylation of 5 in pyridine (rt., overnight) resulting in a yield of 83%. 1-(5-O-Dimethoxytrityl-2-O-tert-butyldimethylsilyl-β-D-Ribofuranosyl)-1,4-dihydropyrimidine-4-one was prepared using standard silylation procedure (Hakimelahi *et al.*, *Can. J. Chem.* 1982, 60, 1106-1113). 1-[5-O-Dimethoxytrityl-2-O-tert-butyldimethylsilyl-3-O-2cyanoethyl-N,N-di-isopropylaminophoramidite-β-D-Ribofuranosyl]-1,4-dihydro-pyri-midine-4-one (7) was prepared by phosphitylation using standard phosphitylation procedure (Tuschl *et al.*, *Biochemistry* 1993, 32, 11658-11668).

Example 5: Synthesis of 1-(5-O-Dimethoxytrityl-2-O-tert-butyldimethylsilyl-3-O-2-cyanoethyl-N,N-diisopropylaminophoramidite-β-D-Ribofuranosyl)-1,4-dihydro-pyrimidine-2-one (6)

Referring to Figure 10, compound 6 was prepared as described in Murray *et al.*, *Biochem.J.* 1995, 311, 487-494.

Example 6: Synthesis of 5'-O-Dimethoxytrityl-2'-O -tert-Butyldimethylsilyl-O<sup>4</sup>-Diphenylcarbamoyl-3-Deaza Uridine 3'-(2-Cyanoethyl N,N-diisopropyl phosphoramidite) (5)

Referring to Figure 11, compound (5) was prepared as described in U.S. Patent No. 5,134,066, except for dimethoxytritylation of O<sup>4</sup>-

Diphenylcarbamoyl-3-deaza-uridine (**2**). The procedure disclosed in the above-mentioned patent afforded desired 5'-O-Dimethoxytrityl-O<sup>4</sup>-Diphenylcarbamoyl-3-deaza-uridine (**3**) in only 10% yield. Therefore the following procedure for dimethoxytritylation of **2** was developed.

5 To the solution of compound **2** (1.95g, 4.45 mmol) in dichloromethane (60 mL), symm-collidine (1.53 mL, 11.6 mmol) was added followed by the addition of silver nitrate (0.99g, 5.8 mmol). After stirring at room temperature for 10 min, dimethoxytrityl chloride was added and the reaction mixture was stirred for additional 1h. Then it was quenched with MeOH (15 mL) and 10 evaporated to dryness. The residue was dissolved in dichloromethane, washed with saturated aq sodium bicarbonate and brine. Organic layer was dried over sodium sulfate and the solvent removed in vacuum. The oily residue was purified by flash chromatography on silica using gradient of EtOAc in Hexanes (30% to 50%) as an eluent to give 3g (88.8%) of the derivative **3**.

15

Example 7: Synthesis of 2-O-t-Butyldimethylsilyl-5-O-Dimethoxytrityl-3-O-(2-Cyanoethyl-N,N-diisopropylphosphoramidite)-β-D-ribofuranosylindole

20 Referring to Figure 13, 1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)indole (**2**) was synthesized from indole and 2,3,5-tri-O--benzoyl-β-D-ribofuranose (**1**) according to the procedure of Szarek *et al.*, *Chem. Comm.* 1975, 648-649). 5-O-dimethoxytrityl β-D-ribofuranosylindole (**3**) was prepared from intermediate **2** by standard deprotection(NaOMe/MeOH) followed by tritylation (DMTCl/Py). 2-O-t-Butyldimethylsilyl-5-O-dimethoxytrityl β-D-ribofuranosylindole (**4**) was prepared from intermediate 25 **3** by standard silylation (32% yield). 2-O-t-Butyldimethylsilyl-5-O-dimethoxytrityl-3-O-(2-cyanoethyl-N,N-diisopropylphosphoramidite)-β-D-ribofuranosylindole (**5**) was prepared from intermediate **4** by 3'-O-phosphitylation (85% yield).

Example 8: Synthesis of 2-O-t-Butyldimethylsilyl-5-O-Dimethoxytrityl-3-O-(2-Cyanoethyl-N,N-diisopropylphosphoramidite)- $\beta$ -D-ribofuranosyl benzimidazole

Referring to Figure 14, 1-(2,3,5-Tri-O-benzoyl- $\beta$ -D-ribofuranosyl) benzimidazole (**2**) was synthesized from benzimidazole and 1-O-acetyl-2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranose (**1**) according to the procedure of Kazimierczuk *et al.*, *Naturforsch.* 1980, 35c, 30-35. 5'-O-dimethoxytrityl  $\beta$ -D-ribofuranoyl benzimidazole (**3**) was prepared from intermediate **2** by standard deprotection (NaOMe/MeOH) followed by tritylation (DMTCl/Py). 2'-O-t-Butyldimethylsilyl-5'-O-dimethoxytrityl $\beta$ -D-ribofuranoyl benzimidazole (**4**) was prepared from intermediate **3** by standard silylation (32% yield). 2'-O-t-Butyldimethylsilyl-5'-O-dimethoxytrityl-3-O-(2-cyanoethyl-N,N-diisopropyl phosphoramidite)- $\beta$ -D- ribofuranoyl benzimidazole (**5**) was prepared from intermediate **4** by 3'-O-phosphitylation (85% yield).

Example 9: Synthesis of 3-( $\beta$ -D-Ribofuranosyl)-Pyridine-2-(4-Nitrophenylethyl)-One and 5-( $\beta$ -D-Ribofuranosyl)-Pyridine-2-(4-Nitrophenylethyl)-One Phosphoramidite.

Referring to Figure 15, treatment of 3-( $\beta$ -D-Ribofuranosyl)-pyridin-2-one (**1** in Figure 6) with TBDMSI-Cl/DMF, NPEOH/Ph3P/DEAD/THF, and TFA, CHCl3, will yield 3-( $\beta$ -D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one (**7**). Treatment of 5-( $\beta$ -D-Ribofuranosyl)-pyridin-2-one (**2** in Figure 6) with TBDMSI-Cl/DMF, NPEOH/Ph3P/DEAD/THF, and TFA, CHCl3, will yield 5-( $\beta$ -D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one (**8**).

Both compounds **7** and **8** is readily converted into phosphoramidites using the standard protocols described above.

Phosphoramidites of the novel analogs of the instant invention are incorporated into polynucleotides using the method of synthesis, deprotection, purification and testing previously described (Wincott *et al.*, 1995 *supra*).

Example 10: 4-Benzylamino-1H-pyridine-2-one or N<sup>4</sup>-benzyl-3-deaza cytosine (figure 12)

Title compound was prepared from 4-hydroxy-1H-pyridin-2-one (**1**) as described in Hung, N.C.; Bisagni, E. *Synthesis*, 1984, 765.

5        **4-Benzylamino-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1H-pyridin-2-one (3) or N<sup>4</sup>-benzyl-2',3',5'-tri-O-benzoyl-3-deaza cytidine:** The suspension of **2** (2.8g, 14.0 mmol) in the mixture of hexamethyldisilazane (50mL) and trimethylchlorosilane (5mL) was refluxed for three hours. The resulting clear solution of trimethylsilyl derivative of **2** was evaporated to dryness. To the 10 solution of the resulting clear oil in dry acetonitrile (40 mL), 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose (7.06g, 14.7 mmol) was added and the reaction mixture was cooled to 0°C. To the above stirred solution trimethylsilyl trifluoromethanesulfonate (3.25 mL, 16.8 mmol) was added drop-wise and the reaction mixture was allowed to warm to a room temperature and left 15 overnight. After that the reaction mixture was diluted with dichloromethane washed with saturated sodium bicarbonate. The precipitate of the unreacted **2**, was isolated by filtration. Then layers were separated and organic layer washed with brine and evaporated. The residue was purified by flash chromatography on silica gel to give 5.5g (60%) of the compound **3**.

20        **4-Amino-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1H-pyridin-2-one (4) or 2',3',5'-tri-O-benzoyl-3-deaza cytidine:** Compound **4** is prepared by catalytic hydrogenolysis (Pd/C) of **3** in ethanol at room temperature.

25        **4-Acetylamino-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1H-pyridin-2-one (5):** Compound **5** is prepared by standard acetylation of the derivative **4** with acetic anhydride in pyridine.

**4-Acetylamino-1-(β-D-ribofuranosyl)-1H-pyridin-2-one (6):** The title compound is prepared by selective deprotection of sugar moiety of derivative **5** with 2M aq NaOH in pyridine-ethanol mixture at -10°C.

30        **4-Acetylamino-1-(5-O-dimethoxytrityl-β-D-ribofuranosyl)-1H-pyridin-2-one (7):** compound **7** is prepared using standard protocols described above.

Example 11: Synthesis of 2'-O-amino pyrimidine nucleoside (8 in Figure 16)

Synthetic methods for preparing 5'-O-NH<sub>2</sub> or 3'-O-NH<sub>2</sub> derivatives of 2'-deoxynucleosides by Mitsunobu inversion are well known in the art. However, applicants attempts to apply this method to the preparation of 2'-O-NH<sub>2</sub>-ribonucleosides resulted in very low yields (< 10%) of desired compounds. Applicant has developed a new and highly efficient process for 5 the synthesis of 2'-O-NH<sub>2</sub>-ribonucleosides and their phosphoramidites.

*3',5'-O-(tetraisopropylsiloxy-1,3-di-yl)-1-β-D-arabinofuranosyl-pyrimidine (2)*

10 Referring to Figure 16, 1-β-D-arabinofuranosyl-pyrimidine, such as 1-β-D-arabinofuranosyl-uracil (2.44g, 10 mmol) was dried by two co-evaporations with anhydrous pyridine and re-dissolved in the anhydrous pyridine. The above solution was cooled (0°C) and solution of 1,3-dichloro-1,1,3,3-tetraisopropylsiloxyane (3.52 mL, 11.0 mmol) in 10 mL of anhydrous 15 dichloroethane was added drop-wise under stirring. The reaction mixture was allowed to warm to room temperature and stirred for additional two hours. The reaction was quenched with MeOH (10 mL) and evaporated to dryness. The residue was dissolved in methylene chloride and washed with saturated NaHCO<sub>3</sub> and brine. The organic layer was evaporated to dryness and coevaporated with toluene to remove traces of pyridine to give 4.8g 20 (98%) of compound 2 which was used without further purification.

*2'-O-phthalimido-3',5'-O-(tetraisopropylsiloxy-1,3-di-yl)-uridine(4)*

25 To the ice-cooled solution of 3',5'-O-(tetraisopropylsiloxy-1,3-di-yl)-1-β-D-arabinofuranosyl-uracil (4g, 8.2 mmol) in dichloromethane trifluoromethane sulfonic anhydride (1.66 mL, 9.86 mmol) was added and the reaction mixture was stirred at -5°C for 30 min. Then it was diluted with dichloromethane and washed with cold 1% aq acetic acid, then with saturated aq sodium bicarbonate and brine. Organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. Resulting derivative 30 3 was dissolved in anhydrous acetonitrile (70 mL) and N-hydroxyphtalimide (1.74g, 10.66 mmol) was added. Solution of DBU (1.6 mL, 10.66 mmol) in

5 acetonitrile (5 mL) was added dropwise to the reaction mixture under vigorous stirring. After 30 min dark orange reaction mixture was diluted with dichloromethane (250 mL) and extracted with saturated aq sodium bicarbonate solution (3x250 mL). Resulted colorless organic layer was washed with brine and evaporated to give 3.6g (70%) of compound 4.

**2'-O-phthalimido-uridine (5)**

10 Triethylamine (1.32 mL, 9.5 mmol) and triethylamine trihydrofluoride (1.55 mL, 9.5 mmol) were added simultaneously to the solution of 2'-O-phthalimido-3',5'-O-(tetraisopropyldisiloxane-1,3-di-yl)-uridine (3g, 4.75 mmol) in dichloromethane. After 1 hour the solvents were removed in vacuo, and remaining residue was dissolved in dichloromethane and evaporated at 35°C. This procedure was repeated 3 times (until Thin Layer Chromatography showed complete conversion of the starting material). The residue was dissolved in dichloromethane and washed with saturated aq sodium bicarbonate and brine. Organic layer was dried over anhydrous sodium sulfate and evaporated to dryness to give 1.56g (85%) of compound 5.

20 2'-O-amino uridine (8) was obtained by hydrolysis with 40% aq methylamine and subsequent crystallization from ethanol.

**5'-O-dimethoxytrityl-2'-O-phthalimido-uridine (6)**

25 The compound 5 (1.5g, 4 mmol) was dried by multiple evaporation with anhydrous pyridine, redissolved in dry pyridine, dimethoxytritylchloride (1.2 eq) was added and the reaction mixture was left under anhydrous conditions overnight. Then it was quenched with methanol (15 ml), evaporated, dissolved in chloroform, washed with saturated aq sodium bicarbonate and brine. Organic layer was dried over sodium sulfate and evaporated. The residue was purified by flash chromatography on silica gel eluting with EtOAc - hexanes mixture (2:3) to give 1.93g (70%) of the corresponding 5'-O-Dimethoxytrityl derivative 6.

30 **5'-O-Dimethoxytrityl-2'-O-phthalimido uridine-3'-(2-Cyanoethyl N,N-diisopropyl) phosphoroamidite (7)**

Standard phosphitylation of **6** according to Tuschl *et al.*, *Biochemistry* 1993, 32, 11658-11668) yielded phosphoramidite **7** in 70% yield.

General Procedure for Phosphitylation: To the ice-cooled stirred solution of protected nucleoside (1 mmol) in dry dichloromethane (20 mL) under argon blanket was added dropwise via syringe the premixed solution of N,N-diisopropylethylamine (2.5eq) and 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (1.2 eq) in dichloromethane (3 mL). Simultaneously via another syringe N-methylimidazole (1 eq) was added and stirring was continued for 2 hours at room temperature. After that the reaction mixture was again ice-cooled and quenched with 15 ml of dry methanol. After 5 min stirring, the mixture was concentrated in vacuo (<40°C) and purified by flash chromatography on silica gel using hexanes-ethylacetate mixture contained 1% triethylamine as an eluent to give corresponding phosphoramidite as white foam.

Phosphoramidites were incorporated into nucleic acid molecules, such as ribozymes and substrates, using the method of synthesis, deprotection, purification and testing previously described (Wincott *et al.*, 1995 *supra*). The average stepwise coupling yields were ~98 %.

Example 12: Synthesis of 2'-O-phthalimido-3',5'-O-(tetraisopropylsiloxane-1,3-di-yl)-N<sup>6</sup>-t-butylbenzoyl adenosine (5 in Figure 17) and 2'-O-amino adenosine nucleoside (9 in Figure 17)

Referring to Figure 17, 9- $\beta$ -D-arabinofuranosyl adenine (12 mmol) was silylated with 1,3-dichloro-1,1,3,3-tetraisopropylsiloxane (4.2 mL, 13.2 mmol) as described for the ara-uridine derivative. The cold solution (-10°C) of the product in anhydrous dichloromethane was treated with trifluoromethanesulfonylchloride (1.53 mL, 14.4 mmol) for 20 min. Resulted solution was diluted with anhydrous dichloromethane and washed with cold (0°C) 1% aq acetic acid, then saturated aq NaHCO<sub>3</sub> and brine. Organic layer was dried over sodium sulfate and evaporated to dryness to give derivative **2**. The residue was dissolved in anhydrous acetonitrile and N-hydroxyphthalimide (2.54g, 15.6 mmol) was added. Solution of DBU (2.33

mL 15.6 mmol) in anhydrous acetonitrile was added to the resulted reaction mixture under vigorous stirring. After 30 min dark orange-brown reaction mixture was worked-up as described for uridine derivative. Resulted 2'-O-phthalimido derivative **4** was dissolved in anhydrous pyridine, 4-tert-butylbenzoyl chloride was added and reaction mixture was left overnight at room temperature. After that it was quenched with methanol (15 mL), solvents removed in vacuo and the residue dissolved in toluene and evaporated to dryness. Resulted oil was dissolved in dichloromethane, washed with saturated aq NaHCO<sub>3</sub> and brine, dried over sodium sulfate and evaporated to dryness. The residue was purified by flash chromatography on silica, using EtOAc-Hexanes (1:2) mixture as an eluent to give 3.5 g (35% on ara-A) of the fully protected synthon **5**.

**2'-O-phthalimido-N<sup>6</sup>-t-butylbenzoyl adenosine (6)**

Markiewicz-group deprotection was performed analogously to the corresponding uridine derivative. Yield 86%.

**2'-O-amino adenosine (9)** was obtained by hydrolysis with 40% aq methylamine and subsequent crystallization from ethanol.

**5'-O-Dimethoxytrityl-2'-O-phthalimido-N<sup>6</sup>-t-butylbenzoyl adenosine (7)**

Standard dimethoxytritylation of 2'-O-phthalimido-N<sup>6</sup>-t-butylbenzoyl adenosine afforded compound **7** with 75% yield.

**5'-O-Dimethoxytrityl-2'-O-phthalimido-N<sup>6</sup>-t-butylbenzoyl adenosine 3'-  
(2-Cyanoethyl N,N-diisopropyl) phosphoroamidite (8)**

Standard phosphitylation of according Tuschl *et al.*, *supra* yielded phosphoramidite **8** in 70% yield.

**Example 13: Synthesis of 2'-O-phthalimido-3',5'-O-(tetraisopropylsiloxydisiloxane-1,3-di-yl)-N<sup>6</sup>-t-butylbenzoyl Guanosine (11 in Figure 18) and 2'-O-amino Guanosine nucleoside (8 in Figure 18)**

Referring to Figure 18, compound **4** is synthesized starting from compound **1**, using the process described in Hansske *et al.*, 1984, *Tetrahedron* 40, 125, incorporated by reference herein. Compounds **8** and

9 can then be synthesized from compound 4 using the procedures described in Figure 7.

Example 14: RNA cleavage reaction catalyzed by ribozymes substituted with 2'-O-amino modifications

5 *RNA cleavage assay in vitro:*

Substrate RNA is 5' end-labeled using [ $\gamma$ -<sup>32</sup>P] ATP and T4 polynucleotide kinase (US Biochemicals). Cleavage reactions are carried out under ribozyme "excess" conditions. Trace amount ( $\leq 1$  nM) of 5' end-labeled substrate and 40 nM unlabeled ribozyme are denatured and 10 renatured separately by heating to 90°C for 2 min and snap-cooling on ice for 10 -15 min. The ribozyme and substrate are incubated, separately, at 37°C for 10 min in a buffer containing 50 mM Tris-HCl and 10 mM MgCl<sub>2</sub>. The reaction is initiated by mixing the ribozyme and substrate solutions and incubating at 37°C. Aliquots of 5  $\mu$ l are taken at regular intervals of time and 15 the reaction is quenched by mixing with equal volume of 2X formamide stop mix. The samples are resolved on 20 % denaturing polyacrylamide gels. The results are quantified and percentage of target RNA cleaved is plotted as a function of time.

20 Referring to Figure 19A, hammerhead ribozymes with 2'-O-amino-substitutions at position 4, 7, 9 or 15.1 were synthesized as described above. These ribozymes were assayed for their ability to cleave target RNA. As shown in Figure 19B, all the ribozymes shown in Figure 19A were capable of catalyzing cleavage of target RNA.

25 Example 15: Synthesis of enzymatic nucleic acids comprising L-nucleotide substitutions

The method of synthesis follows the procedure for normal RNA synthesis as described in Usman *et al.*, *J. Am. Chem. Soc.* 1987, 109, 7845-7854; Scaringe *et al.*, *Nucleic Acids Res.* 1990, 18, 5433-5441; and Wincott *et al.*, 1995, *Nucleic Acids Res.* 23, 2677 (all of these references are

incorporated by reference herein in their entirety) and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-OH, and phosphoramidites at the 3'-OH. Phosphoramidites of L-nucleosides may be incorporated not only into hammerhead ribozymes, but 5 also into hairpin, hepatitis delta virus, VS RNA, RNase P ribozyme, Group I, Group II intron or other catalytic nucleic acids. They are, therefore, of general use in any catalytic nucleic acid structure.

Example 16: Phosphoramidite synthesis of L-ribonucleosides (Scheme 1)

Referring to Figure 21, L-ribose was converted to 1-O-methyl- $\alpha$ , $\beta$ -L-ribofuranoside by action of HCl/MeOH as described (Visser *et al.*, *Recl. Trav. Pays-Bas* 1986, 105, 528-537). This intermediate was further benzoylated by BzCl/py and the resulting 1-O-methyl-2,3,5-tri-O-benzoyl-L-ribofuranoside was subjected to the acetolysis procedure (Ac<sub>2</sub>O/AcOH/H<sub>2</sub>SO<sub>4</sub>). The target 1-O-acetyl-2,3,5-tri-O-benzoyl- $\beta$ -L-ribofuranoside was isolated in ~30% yield from L-Ribose and served as a 10 starting material for the synthesis of L-ribonucleosides in 50-75% yield by Vorbrüggen procedure (Vorbrüggen *et al.*, 1981, *Chem. Ber.* 114, 1234).

The ribose portion of the fully protected ribonucleosides were 15 deprotected by NaOMe/MeOH treatment (Urd) and NaOH/dioxane (Cbz, Abz, Gibu). Subsequently, standard tritylation, silylation, separation of the 2' and 3'-O-TBDMSi isomers and phosphitylation procedures yielded target phosphoramidites.

The phosphoramidites were incorporated into hammerhead 20 ribozymes using general procedures for RNA synthesis and deprotection which have been described previously (Wincott *et al.*, *supra*, incorporated by reference herein in its entirety). Synthesis was carried out on a 394 (ABI) 25 synthesizer using a modified 2.5  $\mu$ mol scale protocol with a 5 min coupling step for 2'-O-TBDMSi protected nucleotides and 2.5 min coupling step for 2'-O-methyl nucleotides. A 6.5-fold excess of a 0.1 M solution 30 phosphoramidite and a 24-fold excess of S-ethyl tetrazole relative to

polymer-bound 5'-hydroxyl was used in each coupling cycle.

All analytical HPLC analyses were performed on a Hewlett Packard 1090 HPLC with a Dionex NucleoPac® PA-100 column, 4 x 250 mm, at 50 °C, as reported (Wincott *et al.*, *supra*).

CGE analyses were performed on a Hewlett Packard 3DCE with a J & W μPAGE™ -5 (5% T, 5% C) polyacrylamide gel-filled column, 75μm I.D. x 75 cm, 50 cm effective length, 100 mM Tris-Borate, 7 M Urea, pH = 8.3, and J & W μPAGE™ Buffer (100 mM Tris-Borate, 7 M Urea, pH = 8.3). Samples were electrokinetically injected using -13 kV for 3-10 sec, run at -13 kV and detected at 260 nm.

10 MALDI-TOF mass spectra were determined on a PerSeptive Biosystems Voyager spectrometer.

**Example 17: Phosphoramidite synthesis of L-ribonucleosides (Scheme 2)**

The above standard Scheme 1 has been used extensively (15 Klubmann *et al.*, *supra* and Ashley, *Supra*) and has certain disadvantages; a) L-Ribose is expensive and the yield of the key intermediate 1-O-acetyl-2,3,5-tri-O-benzoyl-β-L-ribofuranoside, necessary for synthesis of L-ribonucleosides is low (~30%); b) conversion to the *N*-protected 5'-O-DMT derivatives is not very efficient (typical yield is 40-50%) because of difficulties in the selective removal of ribose protecting groups without effecting base protection and tedious isolation of resulting intermediates to be used in tritylation reaction.

20 These problems can be overcome by introduction of orthogonal protection for the 5-O- group during the first step of the synthesis (see Figure 22). This serves two purposes: 1) effective conversion of L-Ribose to the 5-O-tret-butyldiphenylsilyl-1,2,3-O-benzoyl ribofuranose which serves 25 as a precursor for glycosilation is achieved (60% vs 30% in Scheme 1); 2) Orthogonality of 5'-O-TBDPSi group to the acyl type ribose and base protection in fully blocked L-ribonucleosides allows selective removal of this 30 group with effective isolation of 5'-OH intermediate and subsequent efficient

5'-tritylation. Removal of 2',3'-protecting groups from 5'-O-DMT intermediates and isolation of the target 5'-O-DMT-*N*-protected L-ribonucleosides is much more efficient due to lipophilicity of 5'-O-DMT group.

5       Example 18: Synthesis of L-2'-amino-2'-deoxy-uridine and pyrimidine phosphoramidite

10       Referring to Figure 23A, L-Arabinose was converted to the 2,2'-Anhydro-L-uridine (**2**) through 2-Amino- $\beta$ -L-arabinofurano[1',2':4,5]oxazoline (**1**) according to the procedure of Holy, *Coll. Czech. Chem. Commun.* 1972 4072-4087. The opening of 2,2'anhydro ring with lithium azide and subsequent reduction to 2'-amino-uridine **4** was performed as described (Verheyden *et al.*, *J. Org Chem.* 1971, 36,250-254; Hobbs *et al.*, *J. Org. Chem.* 1979, 42, 714-719). The conversion of nucleoside (**4**) to the target phosphoramidite (**6**) was accomplished according to Beigelman *et al.*, *Nucleic Acids Res.*, 1995, 4434-4442.

15       The key intermediate **4** was also converted to 2'-deoxy-2'-azido-cytidine by standard transformation according to Divakar *et al.*, 1982, *J. Chem. Soc. Perkin I*, 1171, protected at N4 by benzoyl group, tritylated and the 2'-N3 function reduced to 2'-amino as in the case of uridine. Above intermediate was further transformed into phosphoramidite using the same procedures for the incorporation of phthaloyl protection and phosphitylation 20 as for Uridine.

Example 19: Synthesis of L-2'-amino-2'-deoxy-purine phosphoramidite

25       Referring to Figure 23B, L-ribonucleosides of A and G, were obtained from L-ribose as shown in Scheme 1 and 2 above. They were *N*-protected using transient protection method (Ti *et al.*, *JACS* 1982, 104, 1316-19) and then 3'- and 5'- protected by Markiewich protecting group. The resulting intermediates **1** were oxidized by CrO<sub>3</sub>/Py and the resulting 2-keto compounds were reduced to the 2'-xylo derivatives **2**. Subsequent tritylation and nucleophilic displacement with LiN<sub>3</sub> according to Robins *et al.*,

(*Nucleosides & Nucleotides* 1992 11, 821-834) resulted in 2'-N3-derivatives 3 . The azido group in 3 was reduced with Ph3P/NH4OH followed by desilylation. The resulting 2'-amino nucleoside 4 was isolated in ~ 60% yield. Transformation of intermediates 4 into phosphoramidites 6 was 5 accomplished analogously to related pyrimidine derivatives according to Beigelman *et al.*, *supra*.

Example 20: Catalytic activity of L-nucleotide-substituted ribozymes

Hammerhead ribozymes were substituted with L-nucleotides at several positions (Figure 24). The relative effect of L-nucleotide-substitution 10 on ribozyme catalytic activity was investigated under standard assay conditions as described, *supra*, in Materials and Methods.

*RNA cleavage assay in vitro:*

Substrate RNA is 5' end-labeled using [ $\gamma$ -<sup>32</sup>P] ATP and T4 15 polynucleotide kinase (US Biochemicals). Cleavage reactions are carried out under ribozyme "excess" conditions. Trace amount ( $\leq$  1 nM) of 5' end-labeled substrate and 40 nM unlabeled ribozyme are denatured and renatured separately by heating to 90°C for 2 min and snap-cooling on ice for 10 -15 min. The ribozyme and substrate are incubated, separately, at 37°C for 10 min in a buffer containing 50 mM Tris-HCl and 10 mM MgCl<sub>2</sub>. 20 The reaction is initiated by mixing the ribozyme and substrate solutions and incubating at 37°C. Aliquots of 5  $\mu$ l are taken at regular intervals of time and the reaction is quenched by mixing with equal volume of 2X formamide stop mix. The samples are resolved on 20 % denaturing polyacrylamide gels. 25 The results are quantified and percentage of target RNA cleaved is plotted as a function of time.

Referring to Figure 25, hammerhead ribozymes with L-nucleotide substitution at one or more positions were all catalytically active to cleave target RNA.

Sequence of ribozymes, target sequence, ribozyme motif and 30 positions of L-nucleotide substitution described in the above and in this

specification are meant to be non-limiting examples, and those skilled in the art will recognize that other nucleic acid catalytic motifs, sequences of target and L-nucleotide substitutions (base, sugar and phosphate modifications) can be readily generated using standard techniques and are hence within 5 the scope of this invention.

Example 21: *In vitro* selection of L-nucleic acid catalysts

*In vitro* selection (evolution) strategies (Orgel, 1979, *Proc. R. Soc. London, B* 205, 435) can be used to evolve L-nucleotide comprising nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages. Any one of a number of different approaches to carry out *in vitro* selection that have been described and reviewed (Joyce, 1989, *Gene*, 82, 83-87; Beaudry *et al.*, 1992, 10 *Science* 257, 635-641; Joyce, 1992, *Scientific American* 267, 90-97; Breaker *et al.*, 1994, *TIBTECH* 12, 268; Bartel *et al.*, 1993, *Science* 15 261:1411-1418; Szostak, 1993, *TIBS* 17, 89-93; Kumar *et al.*, 1995, *FASEB J.*, 9, 1183; Breaker, 1996, *Curr. Op. Biotech.*, 7, 442; Schumacher *et al.*, 1996, *supra*; Nolte *et al.*, 1996, *supra*; Klubmann *et al.*, 1996, *supra*; Breaker, 1997, *Chem. Rev.*, in Press) and any other related approach can 20 be used to evolve and/or select L-nucleotide comprising nucleic acid catalyst and are within the scope of the invention.

These examples are meant to be non-limiting and those skilled in the art will recognize that similar strategies, as described in the present invention, can be readily adapted to synthesize other nucleoside analogs and are within the scope of this invention.

25 Applications

Various ligands can be attached to oligonucleotides using the compounds of Formula I- V, 2'-O-methyl, or 3'-O-methyl nucleosides for the purposes of cellular delivery, nuclease resistance, cellular trafficking and localization, chemical ligation of oligonucleotide fragments. Incorporation of

one or more compounds of Formula I- V into a ribozyme may increase its effectiveness. Compounds of Formula I- V can also be used as potential antiviral agents.

Ribozyme Engineering

5 Sequence, chemical and structural variants nucleic acid catalysts can be engineered using the techniques shown above and known in the art to cleave a separate target RNA or DNA in *trans* (Zaug *et al.*, 1986, *Nature*, 324, 429; Ruffner *et al.*, 1990, *Biochem.*, 29, 10695; Beaudry *et al.*, 1990, *Biochem.*, 29, 6534; McCall *et al.*, 1992, *Proc. Natl. Acad. Sci., USA.*, 89, 10 5710; Long *et al.*, 1994, *Supra*; Hendry *et al.*, 1994, *BBA* 1219, 405; Benseler *et al.*, 1993, *JACS*, 115, 8483; Thompson *et al.*, 1996, *Nucl. Acids Res.*, 24, 4401; Michels *et al.*, 1995, *Biochem.*, 34, 2965; Been *et al.*, 1992, *Biochem.*, 31, 11843; Guo *et al.*, 1995, *EMBO J.*, 14, 368; Pan *et al.*, 1994, *Biochem.*, 33, 9561; Cech, 1992, *Curr. Op. Struc. Bio.*, 2, 605; Sugiyama *et al.*, 1996, *FEBS Lett.*, 392, 215; Beigelman *et al.*, 1994, *Bioorg. Med. 15 Chem.*, 4, 1715; all are incorporated in its totality by reference herein).

Diagnostic uses

20 Ribozymes of this invention may be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of a specific RNA in a cell. The close relationship between 25 ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple ribozymes described in this invention, one may map nucleotide changes which are important to RNA structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets may be defined as important mediators of the disease. These experiments will lead 30 to better treatment of the disease progression by affording the possibility of

combinational therapies (e.g., multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules). Other in vitro uses of ribozymes of this invention are well known 5 in the art, and include detection of the presence of mRNAs associated with related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a ribozyme using standard methodology.

In a specific example, ribozymes which can cleave only wild-type or 10 mutant forms of the target RNA are used for the assay. The first ribozyme is used to identify wild-type RNA present in the sample and the second ribozyme will be used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA will be cleaved by both ribozymes to demonstrate the relative ribozyme efficiencies 15 in the reactions and the absence of cleavage of the "non-targeted" RNA species. The cleavage products from the synthetic substrates will also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus each analysis will require two ribozymes, two substrates and one unknown sample which will be combined into six 20 reactions. The presence of cleavage products will be determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression 25 of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels will be adequate and will decrease the cost of the initial diagnosis. Higher mutant form to wild-type ratios will be 30 correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.

TABLE 1

**Characteristics of naturally occurring ribozymes****Group I Introns**

- Size: ~150 to >1000 nucleotides.
- 5 • Requires a U in the target sequence immediately 5' of the cleavage site.
- Binds 4-6 nucleotides at the 5'-side of the cleavage site.
- Reaction mechanism: attack by the 3'-OH of guanosine to generate cleavage products with 3'-OH and 5' guanosine.
- 10 • Additional protein cofactors required in some cases to help folding and maintenance of the active structure [1].
- Over 300 known members of this class. Found as an intervening sequence in *Tetrahymena thermophila* rRNA, fungal mitochondria, chloroplasts, phage T4, blue-green algae, and others.
- 15 • Major structural features largely established through phylogenetic comparisons, mutagenesis, and biochemical studies [2, 3].
- Complete kinetic framework established for one ribozyme [4, 5, 6, 7].
- Studies of ribozyme folding and substrate docking underway [8, 9, 10].
- 20 • Chemical modification investigation of important residues well established [11, 12].
- The small (4-6 nt) binding site may make this ribozyme too non-specific for targeted RNA cleavage, however, the *Tetrahymena* group I intron has been used to repair a "defective"  $\beta$ -galactosidase message by the ligation of new  $\beta$ -galactosidase sequences onto the defective message [13].
- 25

**RNase P RNA (M1 RNA)**

- Size: ~290 to 400 nucleotides.
- RNA portion of a ubiquitous ribonucleoprotein enzyme.
- 30 • Cleaves tRNA precursors to form mature tRNA [14].
- Reaction mechanism: possible attack by  $M^{2+}$ -OH to generate cleavage products with 3'-OH and 5'-phosphate.
- RNase P is found throughout the prokaryotes and eukaryotes. The RNA subunit has been sequenced from bacteria, yeast, rodents and primates.
- 35 • Recruitment of endogenous RNase P for therapeutic applications is possible through hybridization of an External Guide Sequence (EGS) to the target RNA [15, 16].
- Important phosphate and 2' OH contacts recently identified [17, 18].

**Group II Introns**

- Size: >1000 nucleotides.
- Trans cleavage of target RNAs recently demonstrated [<sup>19, 20</sup>]
- Sequence requirements not fully determined.
- 5 • Reaction mechanism: 2'-OH of an internal adenosine generates cleavage products with 3'-OH and a "lariat" RNA containing a 3'-5' and a 2'-5' branch point.
- Only natural ribozyme with demonstrated participation in DNA cleavage [<sup>21, 22</sup>] in addition to RNA cleavage and ligation.
- 10 • Major structural features largely established through phylogenetic comparisons [<sup>23</sup>].
- Important 2' OH contacts beginning to be identified [<sup>24</sup>].
- Kinetic framework under development [<sup>25</sup>].

**Neurospora VS RNA**

- 15 • Size: ~144 nucleotides.
- Trans cleavage of hairpin target RNAs recently demonstrated [<sup>26</sup>].
- Sequence requirements not fully determined.
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2', 3'-cyclic phosphate and 5'-OH ends.
- 20 • Binding sites and structural requirements not fully determined.
- Only 1 known member of this class. Found in Neurospora VS RNA.

**Hammerhead Ribozyme**

(see text for references)

- 25 • Size: ~13 to 40 nucleotides.
- Requires the target sequence UH immediately 5' of the cleavage site.
- Binds a variable number nucleotides on both sides of the cleavage site.
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2', 3'-cyclic phosphate and 5'-OH ends.
- 30 • 14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent.
- Essential structure features largely defined, including 2 crystal structures [].
- 35 • Minimal ligation activity demonstrated (for engineering through *in vitro* selection) [].
- Complete kinetic framework established for two or more ribozymes [].
- Chemical modification investigation of important residues well established [].

### Hairpin Ribozyme

- Size: ~50 nucleotides.
- Requires the target sequence GUC immediately 3' of the cleavage site.
- 5 • Binds 4-6 nucleotides at the 5' side of the cleavage site and a variable number to the 3'-side of the cleavage site.
- Reaction mechanism: attack by 2'-OH5' to the scissile bond to generate cleavage products with 2', 3'-cyclic phosphate and 5'-OH ends.
- 10 • 3 known members of this class. Found in three plant pathogen (satellite RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory yellow mottle virus) which uses RNA as the infectious agent.
- Essential structural features largely defined [27, 28, 29, 30].
- 15 • Litigation activity (in addition to cleavage activity) makes ribozyme amenable to engineering through *in vitro* selection [31].
- Complete kinetic framework established for one ribozyme [32].
- Chemical modification investigation of important residues begun [33, 34].

### Hepatitis Delta Virus (HDV) Ribozyme

- 20 • Size: ~60 nucleotides.
- Trans cleavage of target RNAs demonstrated [35].
- Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required. Folded ribozyme contains a pseudoknot structure [36].
- 25 • Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2', 3'-cyclic phosphate and 5'-OH ends.
- Only 2 known members of this class. Found in human HDV.
- Circular form of HDV is active and shows increased nuclease stability [37].

---

1. Mohr, G.; Caprara, M.G.; Guo, Q.; Lambowitz, A.M. *Nature*, **370**, 147-150 (1994).
2. Michel, Francois; Westhof, Eric. Slippery substrates. *Nat. Struct. Biol.* (1994), **1**(1), 5-7.
- 35 3. Lisacek, Frederique; Diza, Yolande; Michel, Francois. Automatic identification of group I intron cores in genomic DNA sequences. *J. Mol. Bio.* (1994), **235**(4), 1206-17.
4. Herschlag, Daniel; Cech, Thomas R., Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. 1. Kinetic description of the reaction of an RNA substrate complementary to the active site. *Biochemistry* (1990), **29**(44), 10159-71.

5. Herschlag, Daniel; Cech, Thomas R., Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. @. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. *Biochemistry* (1990), 29(44), 10172-80.

5 6. Knitt, Deborah S.; Herschlag, Daniel. pH Dependencies of the Tetrahymena Ribozyme Reveal an Unconventional Origin of an Apparent pKa. *Biochemistry* (1996), 35(5), 1560-70.

10 7. Bevilacqua, Philip C.; Sugimoto, Naoki; Turner, Douglas H., A mechanistic framework for the second step of splicing catalyzed by the Tetrahymena ribozyme. *Biochemistry* (1996), 35(2), 648-58.

15 8. Li, Yi; Bevilacqua, Philip C.; Mathews, David; Turner, Douglas H., Thermodynamic and activation parameters for binding a pyrene-labeled substrate by the Tetrahymena ribozyme: docking is not diffusion-controlled and is driven by a favorable entropy change. *Biochemistry* (1995), 34(44), 14394-9.

9. Banerjee, Aloke Raj; Turner, Douglas H., The time dependence of chemical modification reveals slow steps in the folding of a group I ribozyme. *Biochemistry* (1995), 34(19), 6504-12.

20 10. Zarrinkar, Patrick P.; Williamson, James R.. The P9.1-P9.2 peripheral extension helps guide folding of the Tetrahymena ribozyme. *Nucleic Acids Res.* (1996), 24(5), 854-8.

11. Strobel, Scott A.; Cech, Thomas R., Minor groove recognition of the conserved G.cndot.U pair at the Tetrahymena ribozyme reaction site. *Science (Washington, D.C.)* (1995), 267(5198), 675-9.

25 12. Strobel, Scott A.; Cech, Thomas R., Exocyclic Amine of the Conserved G.cndot.U Pair at the Cleavage Site of the Tetrahymena Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization. *Biochemistry* (1996), 35(4), 1201-11.

13. Sullenger, Bruce A.; Cech, Thomas R., Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. *Nature (London)* (1994), 371(6498), 619-22.

30 14. Robertson, H.D.; Altman, S.; Smith, J.D. *J. Biol. Chem.*, 247, 5243-5251 (1972).

15. Forster, Anthony C.; Altman, Sidney. External Guide Sequences for an RNA enzyme. *Science (Washington, D.C., 1993-)* (1990), 249(4970), 783-6.

35 16. Yuan, Y.; Hwang, E.S.; Altman, S. Targeted cleavage of mRNA by human Rnase P. *Proc. Natl. Acad. Sci. USA* (1992) 89, 8006-10.

17. Harris, Michael E.; Pace, Norman R.. Identification of phosphates involved in catalysis by the ribozyme Rnase P RNA. *RNA* (1995), 1(2), 210-18.

40 18. Pan, Tao; Loria, Andrew; Zhong, Kun. Probing of tertiary interactions in RNA: 2'-hydroxyl-base contacts between the Rnase P RNA and pre-tRNA. *Proc.Natl.Acad.Sci. U.S.A.* (1995), 92(26), 12510-14.

<sup>19</sup>. Pyle, Anna Marie; Green, Justin B.. Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate. *Biochemistry* (1994), 33(9), 2716-25.

5        <sup>20</sup>. Michaels, William J. Jr.; Pyle, Anna Marie. Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme and Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships. *Biochemistry* (1995), 34(9), 2965-77.

10      <sup>21</sup>. Zimmerly, Steven; Guo, Huatao; Eskes, Robert; Yang, Jian; Perlman, J.; Philip S.; Lambowitz, Alan M.. A group II intron RNA is a catalytic component of a DNA endonuclease involved in intron mobility. *Cell* (Cambridge, Mass.) (1995), 83(4), 529-38.

15      <sup>22</sup>. Griffin, Edmund A., Jr.; Qin, Zhifeng; Michels, Williams J., Jr.; Pyle, Anna Marie. Group II intron RNA is a catalytic component of a DNA endonuclease involved in intron mobility. *Cell* (Cambridge, Mass.) (1995), 2(11), 761-70.

15      <sup>23</sup>. Michel, Francois; Ferat, Jean Luc. Structure and activities of group II introns. *Annu. Rev. Biochem.* (1995), 64, 435-61.

20      <sup>24</sup>. Abramovitz, Dana L; Friedman, Richard A.; Pyle, Anna Marie. Catalytic role of 2'-hydroxyl groups within a group II intron active site. *Science* (Washington, D.C.) (1996), 271(5254), 1410-13.

20      <sup>25</sup>. Daniels, Danette L.; Michels, William J., Jr.; Pyle, Anna Marie. Two competing pathways for self-splicing by group II introns: a quantitative analysis of in vitro reaction rates and products. *J. Mol. Biol.* (1996), 256(1), 31-49.

25      <sup>26</sup>. Guo, Hans C.T.; Collins, Richard A.. Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme derived from *Neurospora* VS RNA. *EMBO J.* (1995), 14(2), 368-76.

30      <sup>27</sup>. Hampel, Arnold; Tritz, Richard; Hicks, Margaret; Cruz, Phillip. 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. *Nucleic Acids Res.* (1990), 18(2), 299-304.

30      <sup>28</sup>. Chowrira, Bharat M.; Berzal-Herranz, Alfredo; Burke, John M.. Novel guanosine requirement for catalysis by the hairpin ribozyme. *Nature* (London) (1991), 354(6351), 320-2.

35      <sup>29</sup>. Berzal-Herranz, Alfredo; Joseph, Simpson; Chowrira, Bharat M.; Butcher, Samuel E.; Burke, John M.. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. *EMBO J.* (1993) 12(6), 2567-73.

40      <sup>30</sup>. Joseph, Simpson; Berzal-Herranz, Alfredo; Chowrira, Bharat M.; Butcher, Samuel E.. Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates. *Genes Dev.* (1993), 7(1), 130-8.

40      <sup>31</sup>. Berzal-Herranz, Alfredo; Joseph, Simpson; Burke, John M.. In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions. *Genes Dev.* (1992), 6(1), 129-34.

45      <sup>32</sup>. Hegg, Lisa A.; Fedor, Martha J.. Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes. *Biochemistry* (1995), 34(48), 15813-28.

<sup>33</sup>. Grasby, Jane A.; Mersmann, Karin; Singh, Mohinder; Gait, Michael J.. Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA. *Biochemistry* (1995), 34(48), 15813-28.

5       <sup>33</sup>. Grasby, Jane A.; Mersmann, Karin; Singh, Mohinder; Gait, Michael J.. Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA. *Biochemistry* (1995), 34(12), 4068-76.

10      <sup>34</sup>. Schmidt, Sabine; Beigelman, Leonid; Karpeisky, Alexander; Usman, Nassim; Sorensen, Ulrik S.; Gait, Michael J.. Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure. *Nucleic Acids Res.* (1996), 24(4), 573-81.

15      <sup>35</sup>. Perrotta, Anne T.; Been, Michael D.. Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis delta virus RNA sequence. *Biochemistry* (1992), 31(1), 16-21.

20      <sup>36</sup>. Perrotta, Anne T.; Been, Michael D.. A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. *Nature (London)* (1991), 350(6317), 434-6.

<sup>37</sup>. Puttaraju, M.; Perrotta, Anne T.; Been, Michael D.. A circular trans-acting hepatitis delta virus ribozyme. *Nucleic Acids Res.* (1993), 21(18), 4253-8.

TABLE 2  
2.5  $\mu$ mol RNA Synthesis Cycle

	<b>Reagent</b>	<b>Equivalents</b>	<b>Amount</b>	<b>Wait Time*</b>
5	Phosphoramidites	6.5	163 $\mu$ L	2.5
	S-Ethyl Tetrazole	23.8	238 $\mu$ L	2.5
	Acetic Anhydride	100	233 $\mu$ L	5 sec
	<i>N</i> -Methyl Imidazole	186	233 $\mu$ L	5 sec
	TCA	83.2	1.73 mL	21 sec
	Iodine	8.0	1.18 mL	45 sec
	Acentonitrile	NA	6.67 mL	NA

\* Wait time does not include contact time during delivery


Other embodiments are within the following claims.

CLAIMS

1. A nucleoside or a nucleotide comprising a nucleic acid sugar portion, wherein the 2' position of said sugar has the formula: 2'-O-NHR<sub>1</sub>, wherein R<sub>1</sub> is selected from a group consisting of H, aminoacyl group, peptidyl group, biotinyl group, cholesteryl group, lipoic acid residue, retinoic acid residue, folic acid residue, ascorbic acid residue, nicotinic acid residue, 6-aminopenicillanic acid residue, 7-aminocephalosporanic acid residue, alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester.

10 2. A nucleoside or a nucleotide comprising a nucleic acid sugar portion, wherein the 2' position of said sugar has the formula: 2'-O-N=R<sub>3</sub>, wherein R<sub>3</sub> is selected from a group consisting of pyridoxal residue, pyridoxal-5-phosphate residue, 13-cis-retinal residue, 9-cis-retinal residue, alkyl, alkenyl, alkynyl, alkylaryl, carbocyclic alkylaryl, and heterocyclic alkylaryl.

15 3. A compound of claim 1 having the formula III:



20 wherein, R<sub>1</sub> is selected from a group consisting of H, aminoacyl group, peptidyl group, biotinyl group, cholesteryl group, lipoic acid residue, retinoic acid residue, folic acid residue, ascorbic

acid residue, nicotinic acid residue, 6-aminopenicillanic acid residue, 7-aminocephalosporanic acid residue, alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester;


5 X is independently a nucleotide base or its analog or hydrogen;

Y is independently a phosphorus-containing group; and

R2 is independently blocking group or a phosphorus-containing group.

4. A compound of claim 2 having the formula IV:

10



15


wherein, R3 is selected from a group consisting of pyridoxal residue, pyridoxal-5-phosphate residue, 13-cis-retinal residue, 9-cis-retinal residue, alkyl, alkenyl, alkynyl, alkylaryl, carbocyclic alkylaryl, and heterocyclic alkylaryl; X is independently a nucleotide base or its analog or hydrogen;

Y is independently a phosphorus-containing group; and

R2 is independently blocking group or a phosphorus-containing group.

5. A nucleoside or a nucleotide comprising a nucleic acid base portion, wherein said base is selected from a group consisting of 2-fluoropyridine-3-yl, pyridine-2-one-3-yl; pyridin-2-(4-nitrophenylethyl)-one-3-yl, 2-bromopyridine-5-yl, 2-bromopyridine-5-yl, pyridin-2-one-5-yl, 2-aminopyridine-5-yl, and pyridin-2-(4-nitrophenylethyl)-one-5-yl.

6. A compound of claim 5 having the formula I:




10 wherein, R1 is independently H; OH; O-R<sub>3</sub>, where R<sub>3</sub> is independently a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; C-R<sub>3</sub>, where R<sub>3</sub> is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; halo; NHR<sub>4</sub> (R<sub>4</sub>=alkyl (C1-22), acyl (C1-22), substituted or unsubstituted aryl); or 15 OCH<sub>2</sub>SCH<sub>3</sub> (methylthiomethyl);

20 X is independently a nucleotide base selected from the group consisting of 2-fluoropyridine-3-yl, pyridine-2-one-3-yl; pyridin-2-(4-nitrophenylethyl)-one-3-yl, 2-bromopyridine-5-yl, 2-bromopyridine-5-yl, pyridin-2-one-5-yl, 2-aminopyridine-5-yl, and pyridin-2-(4-nitrophenylethyl)-one-5-yl;

Y is independently a phosphorus-containing group; and

R<sub>2</sub> is independently a blocking group or a phosphorus-containing group.

7. A compound of claim 1 having the formula II:



5 wherein, R1 is independently H; OH; O-R<sub>3</sub>, where R<sub>3</sub> is independently a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; C-R<sub>3</sub>, where R<sub>3</sub> is independently a compound selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; halo; NHR<sub>4</sub> (R<sub>4</sub>=alkyl (C1-22), acyl (C1-22), substituted or unsubstituted aryl); or OCH<sub>2</sub>SCH<sub>3</sub> (methylthiomethyl);

X is independently a nucleotide base selected from the group consisting of 2-fluoropyridine-3-yl, 2-bromopyridine-5-yl, pyridin-2-one-5-yl, and 2-aminopyridine-5-yl;

Y is independently a phosphorus-containing group; and

R<sub>2</sub> is independently blocking group or a phosphorus-containing group.

8. The compound of claim 1, 2, or 5, wherein said compound is  
20 a nucleotide.

9. The compound of claim 1, 2, or 5, wherein said compound is a nucleotide-tri-phosphate.

10. A polynucleotide comprising the compound of claim 1, 2, or 5 at one or more positions.

5 11. The polynucleotide of claim 10, wherein said polynucleotide is an enzymatic nucleic acid.

12. The enzymatic nucleic acid of claim 11, wherein said nucleic acid is in a hammerhead configuration.

10 13. The enzymatic nucleic acid of claim 11, wherein said nucleic acid is in a hairpin configuration.

14. The enzymatic nucleic acid of claim 11, wherein said nucleic acid is in a hepatitis delta virus, group I intron, VS RNA, group II intron or RNase P RNA configuration.

15 15. The compound of claim 6, wherein said compound is 3-( $\beta$ -D-Ribofuranosyl)-2-fluoropyridine.

16. The compound of claim 6, wherein said compound is 3-( $\beta$ -D-Ribofuranosyl)-pyridin-2-one.

17. The compound of claim 6, wherein said compound is 3-( $\beta$ -D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one.

20 18. The compound of claim 6, wherein said compound is 3-( $\alpha$ -D-ribofuranosyl)-2-fluoropyridine.

19. The compound of claim 6, wherein said compound is 5-( $\beta$ -D-ribofuranosyl)-2-bromopyridine.

20. The compound of claim 7, wherein said compound is 5-( $\alpha$ -D-ribofuranosyl)-2-bromopyridine.

5 21. The compound of claim 6, wherein said compound is 5-( $\beta$ -D-ribofuranosyl)-pyridin-2-one.

22. The compound of claim 7, wherein said compound is 5-( $\alpha$ -D-ribofuranosyl)-pyridin-2-one.

10 23. The compound of claim 6, wherein said compound is 5-( $\beta$ -D-ribofuranosyl)-2-aminopyridine.

24. The compound of claim 6, wherein said compound is 5-( $\beta$ -D-ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one.

25. The compound of claim 7, wherein said compound is 5-( $\alpha$ -D-ribofuranosyl)-2-aminopyridine.

15 26. The compound of claim 1, wherein said compound is 2'-O-amino adenosine.

27. The compound of claim 1, wherein said compound is 2'-O-amino guanosine.

20 28. The compound of claim 1, wherein said compound is 2'-O-amino cytidine.

29. The compound of claim 1, wherein said compound is 2'-O-amino uridine.

30. A mammalian cell comprising the compound of any one of the claims 1-7.

5 31. The mammalian cell of claim 30, wherein said mammalian cell is a human cell.

32. A mammalian cell comprising the compound of claim 10.

33. The mammalian cell of claim 32, wherein said mammalian cell is a human cell.

10 34. A method of making a polynucleotide of claim 10.

35. A method of modulating gene expression using a polynucleotide of claim 10.

36. A pharmaceutical composition comprising a compound of any of claims 1-7.

15 37. A pharmaceutical composition comprising a polynucleotide of claim 10.

38. The compound of claim 1, 2, or 5 wherein said compound is used as an antiviral agent.

39. A process for the synthesis of a 2'-O-amino nucleoside comprising the steps of:

5 contacting a 3' and 5'-protected arabino nucleoside with  
sulfonylating reagent under conditions suitable for the formation of 3'  
and 5'-protected 2'-arabino sulfonyl nucleoside;

displacement of the sulfonyl group from said 2'-arabino sulfonyl nucleoside with *N*-hydroxy-phthalimide in the presence of a strong organic base under conditions suitable for the formation of 3' and 5'-protected 2'-O-*N*-phthaloyl ribonucleoside;

10 deprotection of said phthaloyl ribonucleoside with a fluoride  
containing reagent under conditions suitable for the formation of 2'-O-  
N-phthaloyl ribonucleoside; and

15 contacting said 2'-O-N-phthaloyl ribonucleoside with a reagent selected from a group consisting of alkylamine, hydrazine, *N*-phenyl hydrazine and *N*-alkylhydrazine, under conditions suitable for the formation of said 2'-O-amino nucleoside.

40. The process of claim 39, wherein said sulfonylating reagent is tri-fluoromethane sulfonic anhydride.

41. The process of claim 39, wherein said sulfonylating reagent  
20 is tri-fluoromethane sulfonic chloride.

42. The process of claim 39, wherein said strong organic base is 1,8-diazabicyclo(5.4.0)undec-7-ene.


43. The process of claim 39, wherein said fluoride containing reagent is selected from a group consisting of tetrabutylammonium fluoride and triethylamine trihydrofluoride.

44. The process of claim 39, wherein said alkylamine is aqueous methylamine.

45. The process of claim 39, wherein said *N*-alkylhydrazine is *N*-methylhydrazine.

5 46. A nucleic acid catalyst comprising at least one L-nucleotide substitution.

47. The nucleic acid catalyst of claim 46, wherein said L-nucleotide has the formula V:



10 wherein, X is a nucleic acid base, which may be modified or unmodified, or H; Y is a phosphorus-containing group; R<sub>1</sub> is H, OH or other 2'-modifications; and R<sub>2</sub> is a blocking group or a phosphorus-containing group.

15 48. The nucleic acid catalyst of claim 46, wherein said nucleic acid catalyst has an endonuclease activity.

49. The nucleic acid catalyst of claim 46, wherein said nucleic acid catalyst is capable of cleaving a peptide linkage.

50. The nucleic acid catalyst of claim 47, wherein said nucleic acid catalyst cleaves a separate nucleic acid molecule.

51. The nucleic acid catalyst of claim 46, wherein said nucleic acid catalyst ligates separate nucleic acid molecules.

52. The nucleic acid catalyst of claim 50, wherein said separate nucleic acid molecule is a ribonucleic acid molecule.

5 53. The nucleic acid catalyst of claim 46, wherein said nucleic acid catalyst is a L-nucleic acid catalyst.

54. The nucleic acid catalyst of claim 48, wherein said catalyst is in a hammerhead ribozyme motif.

10 55. The nucleic acid catalyst of claim 48, wherein said catalyst is in a hairpin ribozyme motif.

56. The nucleic acid catalyst of claim 48, wherein said catalyst is in a hepatitis delta virus, group I intron, group II intron, VS RNA or RNase P RNA motif.

15 57. The nucleic acid catalyst of claim 46, wherein said catalyst comprises at least two said L-nucleotide substitutions which may be same or different.

58. The nucleic acid catalyst of claim 46, wherein said catalyst comprises at least one D-nucleotide residue.

20 59. The nucleic acid catalyst of claim 50, wherein said catalyst comprises between 12 and 100 bases complementary to said separate nucleic acid molecule.

60. The nucleic acid molecule of claim 50, wherein said catalyst comprises between 14 and 24 bases complementary to said separate nucleic acid molecule.

5 61. The nucleic acid catalyst of claim 47, wherein said R<sub>1</sub> is OH.

62. The nucleic acid catalyst of claim 47, wherein said R<sub>1</sub> is amino.

63. The nucleic acid catalyst of claim 47, wherein said R<sub>1</sub> is alkoxy.

64. The nucleic acid catalyst of claim 47, wherein said X is selected from the group consisting of adenine, guanine, uracil, and cytosine.

10 65. A mammalian cell comprising the nucleic acid catalyst of claim 46.

66. The cell of claim 65, wherein said cell is a human cell.

67. A pharmaceutical composition comprising the nucleic acid catalyst of claim 46.

15 68. A method for modulating expression of a gene in a mammalian cell by administering to said cell at least one nucleic acid catalyst of claim 46.

20 69. A method of cleaving a separate nucleic acid molecule comprising, contacting the nucleic acid catalyst of claim 46 with said separate nucleic acid molecule under conditions suitable for the cleavage of said separate nucleic acid molecule.

70. The method of claim 69, wherein said cleavage is carried out in the presence of a divalent cation.

71. The method of claim 70, wherein said divalent cation is  $Mg^{2+}$ .

72. The nucleic acid molecule of claim 46, wherein said nucleic acid is chemically synthesized.

73. The hammerhead ribozyme motif of claim 54, wherein said L-nucleotide substitution is at positions 4, or 7 of said hammerhead ribozyme motif.

74. The hammerhead ribozyme motif of claim 54, wherein said L-nucleotide substitution is at positions 4 and 7 of said hammerhead ribozyme motif.

75. The hammerhead ribozyme motif of claim 54, wherein said L-nucleotide substitution is at the 3' terminal position of said hammerhead ribozyme motif.





Fig. 1

### SUBSTITUTE CHEET (rule 26)

Fig. 2








Fig. 3



5/28



5




Fig. 6




Fig. 7




Fig. 8A




Fig. 8B





Fig. 9


i)  $\text{CF}_3\text{SO}_3\text{SiMe}_3/\text{DCE}$ ; ii)  $\text{NH}_3/\text{MeOH}$ ; iii) DMT-Cl/Pyr  
 iv)  $\text{TBDMS-Cl, AgNO}_3$ , Pyr/THF; v) standard phosphorylation



i)  $\text{CF}_3\text{SO}_3\text{SiMe}_3/\text{MeCN}$ ; ii)  $\text{NH}_3/\text{MeOH}$ ; iii) DMT-Cl/Pyr  
 iv) TBDDMS-Cl,  $\text{AgNO}_3$ , Pyr/THF; v) standard phosphorylation

Fig. 10


12/28



i) DPC-Cl, DIPEA; ii) DMT-CI/Pyr; iii) TBDMSCl, AgNO<sub>3</sub>/THF; iv) phosphorylation

**Fig. 11**

Fig. 12



i)  $\text{PhCH}_2\text{NH}_2$ , boiling; ii) glycosylation; iii) hydrogenolysis; iv) introduction of appropriate protection (Ac, TFA, DMF); v)  $2\text{M NaOH}$ ; vi)  $\text{DMT-Cl}$ ; vii)  $\text{TBDMSCl}$ ,  $\text{AgNO}_3/\text{THF}$ ; viii) phosphorylation




Fig. 13





Fig. 14

i.  $\text{Btms}, \text{SnCl}_4$ ; ii.  $\text{NaOMe/MeOH, Dowex 50 \text{ Py}^+, \text{DMTCI/Py}}$ ; iii.  $\text{DMTCI/Py}$ ; iv.  $\text{CIP(OCE)(NiPr}_2\text{)}$




Reagents and Conditions: i: TBDSi-Cl/DMF, ii: NPEOH/Ph<sub>3</sub>P/DEAD/THF, iii: TFA, CHCl<sub>3</sub>, iv: DMTr-Cl/Pyr, v: TBDSi-Cl/AgNO<sub>3</sub>/Pyr/THF, vi: (CEO)P(NiPr<sub>2</sub>)<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>.

Fig. 15


17/28

Fig. 16



18/28

Fig. 17









Fig. 18


*Fig. 19A*

Ribozymes	$k_{obs}$ (min <sup>-1</sup> )
All RNA	0.7
U4-O-Amino	0.007
U7-O-Amino	0.72
A15.1-O-Amino	0.006
A9-O-Amino	0.5

*Fig. 19B*



D-Nucleotides



L-Nucleotides


X = nucleic acid base or H

Y = phosphorus-containing group

R<sub>2</sub> = blocking group or a phosphorus-containing group

R<sub>1</sub> = H, OH or any other 2'-substitution


*Fig. 20*



B = protected nucleic acid base or H

I.  $\text{MeOH}, \text{H}^+$ ; II.  $\text{BzCl}/\text{Py}$ ; III.  $\text{AcOH}, \text{Ac}_2\text{O}, \text{H}_2\text{SO}_4$ ; IV.  $\text{B}^{\text{tms}}, \text{CF}_3\text{SO}_3\text{SiMe}_3$ ; V.  $\text{NaOMe}/\text{MeOH}, \text{Dowex 50 Py}^+$ ; VI.  $\text{DMTCl}/\text{Py}$ ; VII.  $\text{TBDMSSiCl}/\text{AgNO}_3$ ; CIP(OCE)(NiPr<sub>2</sub>)


Fig. 21



**B** = protected nucleic acid base or H

I.  $\text{TBDPsSiCl}/\text{imidazole/DMF}$ ; II.  $\text{BzCl/Py}$ ; III.  $\text{B}^{\text{ms}}, \text{CF}_3\text{SO}_3\text{SiMe}_3$ ; IV.  $\text{F}_2$ ; V.  $\text{DMTCI/Py}$ ; VI.  $\text{OH}^-$ ; VII.  $\text{TBDMSiCl/AgNO}_3$ ; VIII.  $\text{CIP(OCE)(NiPr}_2\text{)}$

Fig. 22




B = modified or unmodified pyrimidine

I. cyanamide, 6N NH<sub>4</sub>OH; II. methyl propiolate; III. LiN<sub>3</sub>; IV. Ph<sub>3</sub>P,NH<sub>4</sub>OH; V. Neffkin's reagent; VI. DMTrCl/Py;  
VII CIP(OCE)(NiPr<sub>2</sub>)

Fig. 23A

26/28



I.  $\text{TiPSiCl}_2/\text{Py}$ ; II.  $\text{CrO}_3/\text{Py}$ ,  $\text{Ac}_2\text{O}$ ; III.  $\text{Na(OAc)}_3\text{BH}$ ; IV.  $\text{TfCl}/\text{DMAP}$ ; V.  $\text{LiN}_3/\text{DMF}$ ; VI.  $\text{Ph}_3\text{P}/\text{NH}_4\text{OH}$ ; VII.  $\text{TBAF}$ ; VIII.  $\text{Nefkin's reagent}$ ; IX.  $\text{DMTCl/Py}$ ; X. phosphorylation

Fig. 23B

## SUBSTITUTE CHEF / rule 26 ✓

27/28




Fig. 24

28/28




Fig. 25

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**